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D I S E A S E S  A N D  D I S O R D E R S
Current advances in research in treatment and recovery: 
Nicotine addiction
Judith J. Prochaska1* and Neal L. Benowitz2
The health harms of combusted tobacco use are undeniable. With market and regulatory pressures to reduce the 
harms of nicotine delivery by combustion, the tobacco product landscape has diversified to include smokeless, 
heated, and electronic nicotine vaping products. Products of tobacco combustion are the main cause of smoking- 
induced disease, and nicotine addiction sustains tobacco use. An understanding of the biology and clinical features 
of nicotine addiction and the conditioning of behavior that occurs via stimuli paired with frequent nicotine dosing, 
as with a smoked cigarette, is important for informing pharmacologic and behavioral treatment targets. We review 
current advances in research on nicotine addiction treatment and recovery, with a focus on conventional combustible 
cigarette use. Our review covers evidence-based methods to treat smoking in adults and policy approaches to 
prevent nicotine product initiation in youth. In closing, we discuss emerging areas of evidence and consider new 
directions for advancing the field.
INTRODUCTION
“To lower nicotine too much might end up destroying the nicotine 
habit in a large number of consumers and prevent it from ever being 
acquired by new smokers.”
– British American Tobacco Company internal document, 
June 1959 (1).
Combusted tobacco use remains a major cause of premature 
disability and death around the world (2). Cigarette smoke contains 
an estimated 7000 different chemical compounds, of which at least 
70 are proven or suspected human carcinogens including arsenic, 
benzene, formaldehyde, lead, nitrosamines, and polonium 210. 
Tobacco smoke also contains poisonous gasses: carbon monoxide, 
hydrogen cyanide, butane, toluene, and ammonia. Little cigars and 
water pipes deliver similar toxicants.
Tobacco smoking causes about half a million U.S. deaths 
annually, of which 50,000 are among nonsmokers exposed to 
secondhand smoke (3, 4). More than half of all long-term smokers 
die from a tobacco-caused disease, with an average loss of at least 
10 years of life (3). Smoking causes 87% of lung cancer deaths, 61% 
of pulmonary disease deaths [chronic obstructive pulmonary disease 
(COPD) and emphysema], and one in three cancer deaths. In the 
50 years following the U.S. Surgeon General’s first report on tobacco 
(1964–2014), 20 million Americans died from smoking, and an 
estimated 1 billion people will die worldwide this century (3, 5). For 
every person who dies from smoking, at least 30 people live with 
serious smoking-related illnesses costing >$300 billion annually, with 
nearly $170 billion in direct medical costs and $156 billion in lost 
worker productivity (3, 6).
The health harms of combusted tobacco use are now undeniable 
(7). With market and regulatory pressures to reduce the harms of 
nicotine delivery by combustion, the tobacco product landscape has 
diversified (Table 1). Nicotine now comes in smokeless tobacco 
prepackaged pouches (i.e., snus tobacco), in electronic devices that 
heat nicotine to an inhalable aerosol from a plug of tobacco (i.e., 
heated or heat-not-burn tobacco) or from an e-liquid (nicotine 
vaping device; e.g., e-cigarette, vape pen, and pod), and in pharmaceutical- 
grade nicotine replacement therapies (NRTs) (i.e., gum, lozenge, 
patch, nasal spray, mouth spray, and inhaler). Cigars come in a variety 
of sizes down to little filtered cigars, some discernible from cigarettes 
only by their tobacco leaf wrapper. Despite the diversification, 
conventional combusted cigarettes remain, by far, the most com-
mon nicotine product used by adults in the United States and in 
most places globally. Worldwide, there are approximately 1 billion 
smokers (5).
While products of tobacco combustion are the main cause of 
smoking-induced disease, nicotine addiction sustains tobacco use 
(8). Nicotine addiction, in the form of cigarette smoking, causes more 
harm to public health than any other drug addiction. Reflected in 
the quote above, at least since the 1950s, the tobacco industry has 
researched and recognized, decades before it became generally 
understood in the scientific community, that nicotine is an addictive 
drug and central to their business (9). An understanding of the clinical 
features of nicotine addiction and the behavioral conditioning that 
occurs with frequent nicotine dosing is important for informing 
pharmacologic and behavioral treatment targets.
We review current advances in research on nicotine addiction 
treatment and recovery. The “Tobacco Product Use and Nicotine 
Addiction” section covers the changing landscape of nicotine products 
with comparison of use patterns among adults and adolescents in 
the United States. The pharmacology of nicotine and effects on the 
brain are then reviewed, with consideration of particularly vulnera-
ble populations. The “Treating Nicotine Addiction in Adults, with a 
Focus on Conventional Cigarettes” section focuses on treatment of 
nicotine addiction with attention to counseling and behavioral 
approaches and cessation medications. The tobacco treatment litera-
ture is far more developed for combusted cigarettes and relatively 
sparse in other product areas. We focus on adults given develop-
mental differences in adolescents’ preferred nicotine product type, 
use patterns, addiction profile, and treatment efficacy. The tobacco 
treatment literature with adolescents largely consists of failed smoking 
cessation trials (10), and while youth nicotine vaping is drawing 
public health concern and policy attention, no study, to date, has 
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evaluated an intervention to treat e-cigarette use in adolescents. 
The “Tobacco Control Population-Based and Policy Approaches” 
section gives greater attention to use in youth with review of 
the evidence for tobacco control policy interventions. The “Discus-
sion: What Evidence Is Needed” section closes with discussion of 
emerging areas and consideration of new directions for advancing 
the field.
TOBACCO PRODUCT USE AND NICOTINE ADDICTION
Patterns of tobacco use in the United States
In 2017, 47.4 million U.S. adults (19%) reported every day or some 
day use of a tobacco product, which includes e-cigarettes (in the 
United Stated, electronic nicotine delivery systems are classified and 
regulated as tobacco products) (11). Among U.S. adult tobacco 
users, 87% (41.1 million) smoked combusted tobacco products (11). 
The prevalence of tobacco product use was 14% (34.3 million) cigarettes; 
4% (9.3 million) cigars, cigarillos, and little filtered cigars; 3% 
(6.9 million) e-cigarettes; 2% (5.1 million) smokeless tobacco; and 
1% (2.6 million) pipes, water pipes, or hookah (11). Among cigarette 
smokers, 76% smoked daily (12).
In contrast, among U.S. adolescents, e-cigarettes exceed conven-
tional cigarette use. In 2018, past 30-day e-cigarette use was reported 
by 21% of high school (3.05 million) and 5% of middle school 
(570,000) students, and combustible cigarette use was reported by 
8% of high school (1.1 million) and 2% of middle school (200,000) 
students (13). From 2017 to 2018, e-cigarette use increased by 78% 
among high school and 49% among middle school students. Pre-
liminary U.S. data for 2019 indicate that e-cigarette use has climbed 
further to 27.5% among high school students with most reporting 
use of sweet-flavored (65.9% fruit, 38.7% candy, and 4.2% chocolate) 
and minty/menthol–flavored (63.9%) e-cigarette products, while 
use of combustible cigarettes has further declined to 5.8% (14). To 
address youth e-cigarette use, the U.S. Food and Drug Administration 
(FDA) is considering banning all unauthorized non–tobacco-flavored 
e-cigarettes.
Among adolescents who use tobacco, 7 in 10 use a flavored product 
(15). For youth, flavored tobacco products are highly appealing and 
Table 1. Diversity of tobacco products.  
Product Definition Types pH Nicotine levels
Cigarette
Tobacco rolled in paper  
for smoking
A typical cigarette weighs <1 g; 
regular length (70 mm long), 
king (84 mm), 100s (100 mm), 
and 120s (120 mm)
Acidic, inhalable, pH 5.5–6 Average in rod, 13.5 mg 
(range: 11.9–14.5 mg); 
nicotine yield to the 
smoker: 1–1.5 mg/cigarette
Cigar
Air-cured, fermented tobacco 
wrapped in material made at 
least, in part, of tobacco leaf
Small filtered cigars (0.9–1.3 g 
tobacco), cigarillos (1.3–2.5 g tobacco), 
and large (premium) cigars
pH 6.5–8.0 inhalable and/or 
buccal depending on 
product pH
Nicotine content ranges 
from 10 to 444 mg and 
dependent on weight of 
the cigar
Blunt
Cannabis filled in a 
hollowed-out cigarillo shell
No pH data available Nicotine intake much lower 
than from cigarette or 
cigar smoking, but, based on 
animal studies, could 
enhance rewarding effects of 
delta 9-tetrahydrocannbinaol
Smokeless tobacco
Tobacco inserted between lip 
and gum or snorted into 
the nose rather than 
smoked by the user
Snuff (ground tobacco), snus 
(ground tobacco in a tea bag–like 
pouch), chew (shredded 
tobacco)
Products range from more 
acidic, pH 5.2–7.1, to more 
alkaline for greater buccal 
absorption, pH 7.6–8.6
Nicotine concentrations vary, 
range of 0.2 to 34 mg/g, 
the more alkaline 
products are capable of 
delivering higher levels of 
nicotine
Waterpipe/Hookah
Charcoal-heated flavored 
tobacco passed through a 
water-filled chamber that 
cools the smoke
Water tobacco is a mixture of 
dried fruit, molasses and 
glycerin, and conventional 
tobacco leaf
pH 3.8–5.8 Average of 1.13 mg/g and 
high of 3.30 mg/g for 
product containing 
nicotine; nicotine-free for 
herbal (nontobacco) varieties
Heated tobacco
Electronic devices that heat 
reconstituted tobacco 
sticks treated with a 
glycerin humectant to 
deliver an aerosol
IQOS, Glo, and Ploom Tech pH 5.5–6 Nicotine delivery can match 
that of conventional cigarettes
E-cigarette
Electric devices that produce 
an aerosol from a liquid 
that typically contains 
nicotine, propylene glycol, 
vegetable glycerin, and 
flavorings
Cigalikes/e-pens, tank systems, 
pods/nicotine salts (e.g., 
benzoate and lactate)
Free base e-liquid: alkaline, 
pH 7–9; nicotine salts: 
acidic, inhalable, pH 
3.5–6.8
E-liquid nicotine content 
from 0 to 100 mg/ml. 
Nicotine delivery can 
match that of 
conventional cigarette but 
varies by device design 
(heating temperature), 
e-liquid nicotine content, 
and user behavior
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decrease perceptions of harm and addictiveness (16). With the 
explicit intent of protecting youth from smoking initiation, in 2009, 
the U.S. Congress banned characterizing flavors from traditional 
cigarettes except for menthol (17). The 2009 flavored cigarette ban 
reduced the U.S. youth smoking prevalence; however, menthol 
cigarette use among adolescent smokers has increased (18). In 2013, 
the FDA concluded that menthol cigarettes lead to increased smoking 
initiation among youth and young adults, greater addiction, and 
decreased success in quitting smoking (19). In 2017, menthol ciga-
rettes comprised 36% of the U.S. cigarette market, the highest pro-
portion on record (20).
Dual use of tobacco products is also on the rise (21, 22). The most 
recent surveillance data show that 3.7% (9 million) of adults (11), 11% 
(1.7 million) of high school students, and 2% (270,000) of middle school 
students (13) use two or more tobacco products. The most prevalent 
dual tobacco combination for adults and adolescents was combustible 
cigarettes and e-cigarettes, followed by cigarettes and cigars for adults, 
and e-cigarettes and cigars for adolescents. Motivations for dual use 
among adults include use of smokeless tobacco and e-cigarettes in 
places where combustible cigarette smoking is prohibited, as a form 
of harm reduction, and to support quitting smoking (23).
While e-cigarette use may represent harm reduction for adult 
smokers, few would suggest a benefit of nicotine vaping in adoles-
cence when the brain is still developing. Unknown is the extent to 
which e-cigarette use among youth is a fad, will lead some to 
long-lasting primary nicotine addiction, and/or may be a gateway 
to cigarette smoking. The National Academies of Sciences 2017 
review concluded that there is substantial evidence that e-cigarette 
use increases the risk of ever smoking combustible cigarettes among 
youth and young adults, but whether this is trial use versus sustained 
use could not be determined from the literature (24). Two recent 
prospective observational studies of U.S. adolescents reported that 
among never smokers, e-cigarette use was significantly associated 
with both initiating and continuing combustible cigarette use (25, 26). 
A potential confounder is cannabis use, which has a high concor-
dance with e-cigarette use. A third prospective study examined the 
question of whether adolescents are engaging in e-cigarette trial use 
versus dependent use (27). The sample was adolescent past-month 
e-cigarette users reporting 10+ uses in their lifetime at baseline. At 
12-month follow-up, 80% continued their e-cigarette use, daily use 
increased from 14.5 to 29.8%, and the adolescents tended to “graduate 
up” to higher–nicotine content pod-type devices such as JUUL. The 
youths’ top e-cigarette flavor preferences—fruit, mint/menthol, and 
candy—remained stable over time. The adolescents’ self-rated level 
of e-cigarette addiction correlated significantly with their level of 
nicotine exposure, as measured by the nicotine metabolite biomarker 
of urinary cotinine (28).
The increase in e-cigarette use in youth over the past 5 years has 
been mirrored by a decrease in cigarette smoking, which raises the 
question of whether vaping may be diverting some youth away from 
cigarette smoking. Whether the greater e-cigarette than conven-
tional cigarette use among adolescents will lead to sustained popu-
lation declines in adult smoking is as yet unknown.
Nicotine addiction: Definitions, biology, clinical features, 
and vulnerable groups
Defining nicotine addiction
In this review, we refer to the compulsive use of nicotine and tobacco 
products as an addiction, based on the definition provided in the 
1988 U.S. Surgeon General’s report, referring to “behavior of 
repetitively ingesting mood-altering substances by individuals” (29). 
However, it should be noted that definitions such as that from the 
World Health Organization (WHO) define addiction as “a behav-
ioral pattern in which the use of a given psychoactive drug is given 
a sharply higher priority over other behaviors that once had a sig-
nificantly higher value” (30). There is no question that cigarette 
smoking fits both definitions, but with the advent of noncombusted 
forms of nicotine (like e-cigarettes), which are considered to be much 
less harmful than cigarette smoking (but not necessarily safe), some 
clinicians and vapers (those who use e-cigarettes) object to the term 
addiction because they view pure nicotine dependence as not being 
detrimental to health. Thus, while we use the term addiction to refer 
to being unable or unwilling to stop when it is clearly in one’s interest 
to do so, we acknowledge some controversy as to its application to 
noncombusted tobacco product use.
Today, the health harms of smoking are well known, and most 
smokers want to quit. However, most attempts to quit smoking fail. 
The statistics are striking: (i) 68% of smokers in the United States 
want to stop smoking, and 55% quit for 24 hours in a given year 
(many more smokers attempt to quit but are unable to make it a full 
day) (31); (ii) 60% of those who quit for a day relapse by 1 week; and 
(iii) only 7% of quit attempts are sustained 6 months, and 45% of 
those end in relapse (31).
Ultimately, more than 90% of smokers try to quit; most make 
multiple quit attempts, and about half quit smoking long term, al-
though most do not achieve abstinence until after age 30. That most 
smokers attempt to quit each year and less than 4% of quit attempts 
are sustained long term illustrates the loss of control of drug use 
with addiction. Factors that influence the development and mainte-
nance of nicotine addiction are complex and include the drug’s 
pharmacologic effects and tobacco product design; genetics; learned 
factors, such as conditioning of stimuli through frequent nicotine 
dosing; and sociocultural exposures including family and peer use 
and pervasive tobacco marketing and retail availability (8).
Nicotine and its pharmacology
Nicotine is an alkaloid that occurs in highest concentrations in leaves 
of the tobacco plant (Nicotiana tabacum). Approximately 95% of 
the alkaloid content of tobacco is nicotine, along with 5% of minor 
alkaloids including anabasine, anatabine, and norcotinine. Easy to 
extract, nicotine from tobacco plants is used almost exclusively in 
nicotine medications and e-cigarettes.
Nicotine chemistry and pharmacokinetics. Nicotine is a tertiary 
amine that can exist in a charged (ionized) or uncharged (unionized) 
form, depending on pH. Nicotine is a weak base with a pKa (where 
Ka is the acid dissociation constant) of 8.0 such that, at physiological 
pH (7.4), 69% is ionized and 31% is unionized. The unionized (also 
known as free base) form of nicotine passes readily though mem-
branes, such as the buccal mucosa, such that the pH of smokeless 
tobacco influences the rate and extent of systemic nicotine absorp-
tion. The more alkaline (higher pH), the more rapidly nicotine is 
absorbed from smokeless tobacco. Cigarette smoke has an acidic pH 
of about 5.5 to 6, so little nicotine is absorbed through the mouth, 
while large cigars have an alkaline pH, facilitating oral absorption. 
The differences in pH of tobacco products depends on the strains of 
tobacco used and curing processes, as well as on chemicals used in 
processing. The pH of nicotine solutions also influences the phar-
macology of e-cigarettes. The earliest forms of e-cigarette liquid 
(e-liquid) contained mostly nicotine in free base form (pH 7 to 9), 
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which results in a considerable nicotine-related harshness during 
inhalation. Recently, e-liquids have used nicotine salts (such as 
benzoate or lactate), with acidic pH (5.5), similar to that of cigarettes. 
This results in less irritation with inhalation and has been implicated 
in the current popularity of e-cigarette use in never-smoker ado-
lescents (32).
When cigarette smoke is inhaled, nicotine moves quickly to the 
lungs, arterial blood, and the brain in only 15 to 20 s (33), where it 
exerts its addiction-related effects. Rapidity of delivery to the brain 
is thought to be an important factor in the abuse liability of inhaled 
nicotine compared to other routes of nicotine administration. The 
importance of rapid delivery relates to higher arterial concentrations, 
nearly immediate psychological effects, and the ability to titrate doses 
to desired effects. Higher arterial levels also allow the smoker to 
overcome effects of tolerance to the desired psychological effects of 
nicotine. Inhaled nicotine from e-cigarettes potentially carries a 
similar abuse liability to that of tobacco cigarettes, but empirical 
data, to date, suggest that it is not the case. It appears that the depen-
dence liability of inhaled nicotine is also influenced by other con-
stituents of tobacco smoke, such as chemicals that inhibit monoamine 
oxidase (MAO), an enzyme that degrades neurotransmitters released 
by nicotine, discussed in more detail later. Furthermore, dependence 
on nicotine from medications (e.g., nicotine patches, gum, and lozenge) 
that deliver nicotine slowly appears to be low.
On average, smokers absorb 1 to 1.5 mg of nicotine from a cigarette 
(33). Nicotine has an average half-life of 2 hours, but the half-life 
can be affected by genetic and environmental factors. With regular 
smoking, nicotine levels rise in the blood over 4 to 6 hours, plateau 
throughout the day, and then decline overnight. Thus, although 
each cigarette produces a spike of arterial nicotine with a rapid 
decline between cigarettes, in a regular daily smoker, the brain is 
exposed to nicotine for 24 hours each day. This duration of expo-
sure has implications for the development of tolerance and with-
drawal symptoms, as discussed later.
Nicotine is primarily metabolized (via oxidation) by the liver 
enzyme, CYP2A6 (34). The main proximate metabolite is cotinine, 
which has been widely used as a biomarker of nicotine exposure. 
CYP2A6 activity is strongly influenced by genetic and environmental 
factors. Genetic variants associated with a slow rate of nicotine 
metabolism are more common in people of Asian and African 
descent compared to Caucasians. Environmental influences on 
nicotine metabolism include estrogen: Premenopausal women 
metabolize nicotine faster than men; women taking estrogen- 
containing birth control pills metabolize nicotine faster than women 
who do not; and pregnant women metabolize nicotine fastest of all. 
Various foods and medications can also affect nicotine metabolism. 
The rate of metabolism affects smoking behavior, with faster me-
tabolizers smoking more cigarettes per day (presumably to titrate 
desirable nicotine levels in blood) (35).
Brain mechanisms. Nicotine acts on nicotinic acetylcholine re-
ceptors (nAChRs) that are found throughout the nervous system. 
Acetylcholine is a neurotransmitter that acts on nearly every organ 
in the body, and similarly, nicotine affects nearly every organ in the 
body. Many subtypes of nAChRs are present in the brain. Each 
receptor is composed of five subunits. Eleven nAChR subunits are 
expressed in the brain, including 2 to 7, 9, 10, and 2 to 4 
(36). Nicotinic receptors can be heteromeric, with  and  subunits, 
or homomeric, with five 7 subunits. The most abundant nAChRs 
in the brain are 42 and 7 (homomeric). The 42 nAChR can 
also contain 5 and/or 6 subunits, which alter receptor physiology 
and contribute to differences in susceptibility to nicotine depen-
dence. Another widespread receptor subtype is 34, which mediates 
cardiovascular and other autonomic effects of nicotine.
When nicotine binds to the outside of a nAChR, an ion channel 
opens, allowing entry of calcium, sodium, or potassium ions. Initially, 
the receptor is activated, which is then followed by desensitization. 
nAChRs can exist in three conformational states: closed, in the resting 
state; open, allowing ion entry and membrane depolarization; and 
desensitized, where the receptor is unresponsive to nAChR agonists 
(37). The sensitivity to nicotine and the pharmacodynamics of 
response (such as duration of desensitization) vary based on 
the particular receptor type, which translates into differential de-
velopment and time course of tolerance to different nicotine 
effects.
Mood, cognitive, and relaxation effects of smoking are thought 
to occur via nicotine’s stimulation of presynaptic nAChRs (8). 
Activation of these receptors results in facilitation of release of 
various neurotransmitters, including (i) dopamine, which is known 
to signal pleasure and is released by all drugs of abuse; (ii) norepi-
nephrine and acetylcholine, which enhance vigilance and cognitive 
function; (iii) glutamate, which enhances memory and learning; 
(iv) serotonin, which affects mood; and (v) -aminobutyric acid (GABA) 
and endorphins, which ameliorate stress and anxiety.
The neural connections involving nicotine actions are complex. 
Nicotine affects the mesolimbic dopamine system, which is central 
in the neurobiology of addiction. Nicotine binds to nAChRs in the 
ventral tegmental area, which then activate dopamine neurons in 
the nucleus accumbens. The firing of dopamine neurons is modu-
lated by GABAergic and glutaminergic neurons such that glutami-
nergic neurons enhance firing, while GABAergic neurons inhibit 
firing. The high-affinity 42 nAChRs are located on the inhibitory 
GABAergic neurons, while the 7 nAChRs are located on the excit-
atory glutaminergic nAChRs. The actions of nicotine on the inhibitory 
GABAergic neurons desensitize rapidly, while the actions on the 
7 nAChR desensitize more slowly. Thus, over time, nicotine exposure 
results in a greater and persistent activation of dopamine neurons, 
actions that may promote the rewarding effects of nicotine (38). 
Nicotine may also interact with other drugs of abuse via interactions 
with opioid and cannabinoid receptor pathways (39, 40). The im-
portance of various nAChR subunits has been determined using genetic 
knockout mice. The 2 nAChR subunit is necessary for nicotine- 
related reward, while the 4 subunit influences nicotine withdrawal 
symptoms (41). The 6 nAChR subunit is important in activation of 
dopaminergic neurons, while the 5 subunit modulates the aversive 
effects of nicotine (42). Aversion to nicotine appears to be an 
important determinant of dependence, as people with genetic variants 
of the 5 nAChR subunit associated with less aversiveness are at higher 
risk of nicotine dependence (43).
With prolonged exposure to nicotine, structural changes occur 
in the brain. Most notably, there is up-regulation of nAChRs, with 
greater density of nAChRs in many parts of the brain. This up- 
regulation has been thought to be a response to nAChR desensitization, 
but more recent studies suggest that up-regulation occurs by a chap-
eroning mechanism (44). That is, nicotine appears to bind to 
nAChRs in the cell to facilitate assembly and chaperoning the re-
ceptors to the cell membrane. Up-regulation of nAChRs is thought 
to be related to the development of physical dependence, including 
the withdrawal symptoms that occur when nicotine exposure stops. 
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Presumably, the up-regulated receptors that are inactive in the pres-
ence of nicotine become sensitive again during nicotine abstinence.
Two other neurotransmitter systems appear to play important 
roles in nicotine dependence. Hypocretins are neuropeptides that 
regulate the effects of nicotine on reward centers in the brain, found 
to influence nicotine self-administration in animals (45). The insular 
cortex contains a high density of hypocretin-1–containing neurons. 
Immediate and sustained reduction in craving and withdrawal 
symptoms has been observed in hospitalized smokers following stroke 
damage to the insular cortex compared to hospitalized smokers without 
brain lesions (46).
Tolerance develops to many of the effects of nicotine with re-
peated exposures. In time, the brain adapts to the persistent effects to 
normalize brain function and related behavior. When nicotine exposure 
is stopped, brain function is disrupted and put in a state of with-
drawal. Nicotine withdrawal results in activation of the corticotropin- 
releasing factor (CRF) system involved in the hypothalamus pituitary 
adrenal stress response. Withdrawal symptoms, such as anxiety and 
stress, are thought to be mediated, at least in part, by a relative un-
deractivity of the dopaminergic system and hyperactivity of the CRF 
system. Antagonists of the CRF receptor reduce the anxiogenic 
effects of nicotine withdrawal and reduce self-administration of nico-
tine in the withdrawal state (47).
Dependence on nicotine appears to be augmented by other 
chemicals in cigarette smoke. Acetaldehyde, for example, increases 
self- administration of nicotine in animals. Particular chemicals in 
cigarette smoke inhibit the activity of the enzyme MAO in the brain 
(48). MAO catalyzes the breakdown of dopamine, norepinephrine, 
and serotonin, which are neurotransmitters that mediate nicotine 
reward. In animals, administration of drugs that inhibit MAO 
enhances nicotine self-administration. MAO-inhibiting medications 
have been used to treat depression. As discussed later, people with 
psychiatric illness, including depression, are more likely to smoke 
and to be more highly dependent. One theory is that MAO inhibi-
tion from smoking may have beneficial effects in depressed smokers. 
However, while acute smoking abstinence is associated with depres-
sive symptoms and anxiety, prolonged quitting generally improves 
mood, including among smokers with psychiatric disorders such 
as depression (49).
Clinical features of nicotine addiction
Positive psychoactive effects of nicotine include pleasure, stimula-
tion, and mood modulation, with reduced anxiety and stress (8). A 
smoker often reports pleasure and stimulation with the first cigarette 
of the day, stimulation and increased concentration from smoking 
during repetitive tasks during the day, and relaxation at times of 
stress and at bedtime. However, tolerance develops to many of nicotine’s 
effects such that even within the day, the pleasure experienced from 
each cigarette diminishes. As nicotine levels decline, withdrawal 
symptoms develop, reversing nicotine’s positive effects. Thus, an 
abstinent smoker may feel anxious, irritable, and depressed and 
have problems concentrating. Hedonic dysregulation (a reduced 
ability to experience pleasure) may be experienced, presumably 
related to a relative deficiency of dopaminergic activity. Nicotine 
increases metabolic rate and suppresses appetite, resulting in 
smokers, on average, weighing less than nonsmokers. During nico-
tine withdrawal, smokers typically experience hunger and gain 
weight.
Some of the perceived benefits of nicotine are mediated by the 
reduction of adverse effects of nicotine withdrawal (termed nega-
tive reinforcement). Thus, the pharmacologic role of nicotine in 
addiction is a combination of providing positive and negative 
reinforcement (Fig. 1). For daily smokers, there is a daily cycle during 
which nicotine levels rise in the blood, substantial tolerance develops 
during the day, and smoking occurs to relieve withdrawal symptoms. 
Some highly addicted smokers wake at night to smoke because of 
withdrawal symptoms. In contrast, some light and intermittent 
smokers smoke in response to particular cues, without experiencing 
withdrawal symptoms, and are thought to smoke just for positive 
reinforcement.
Nicotine dependence severity is best measured by the number 
of cigarettes smoked per day and the time to first cigarette upon 
wakening. The two items make up the heaviness of smoking index 
(HSI) (50). Number of cigarettes smoked per day is a measure of both 
daily nicotine intake and the frequency of nicotine self- administration. 
Fig. 1. The nicotine addiction cycle. 
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Time to first cigarette is a measure of physical dependence and 
the intensity of withdrawal symptoms after overnight abstinence. 
The two HSI items significantly correlate with biomarkers of 
tobacco exposure, accounting for 20 to 30% of the variance in 
measures of alveolar carbon monoxide, nicotine, and urinary 
cotinine (50). Research conducted by Altria with funding from 
Philip Morris USA concluded that the HSI items were the most 
important factors correlating with biomarkers of exposure (51). 
The HSI is associated with smoking-induced deprivation, measured 
as prioritization of cigarettes over household essentials such as 
food (52). Both items are used for dosing nicotine replacement 
medications, discussed in the “Tobacco Control Population- 
Based and Policy Approaches” section, with higher doses for 
heavier smokers and those who smoke within 30 min of waking. 
HSI scores predict difficulty with quitting smoking (53) and the 
likelihood of developing tobacco-related diseases, such as heart 
disease, COPD, and lung cancer (54, 55). Smoking affects gene 
expression, and the two HSI items correlate with candidate genes 
previously associated with cocaine, alcohol, and heroin addiction 
(56). The rate of nicotine metabolism also correlates significantly 
with the HSI (57). The HSI items have demonstrated very good 
test-retest reliability among adolescents and adults (58, 59). The 
HSI items come from the longer Fagerström Test for Cigarette 
Dependence (60). A similar instrument has been developed to assess 
severity of dependence on e-cigarettes (61) with demonstrated 
validity, including among adolescents (28).
While nicotine is necessary for tobacco dependence, conditioned 
behavior is also an important factor and has strong implications for 
behavioral treatment. When a person quits smoking, cravings for 
cigarettes persist long after nicotine withdrawal symptoms have 
resolved (62). A smoker typically associates smoking with particular 
situations, moods, or environmental factors that become cues to 
smoke. Thus, smokers often smoke after a meal, with coffee or alcohol, 
while driving, and/or with friends who smoke. Smoking a cigarette 
reverses the negative mood, anxiety, and irritability of nicotine with-
drawal (62). This repeated experience can generalize to a condition 
in which anxiety or depression from any cause becomes a cue to 
smoke. The act of smoking, with the handling, hit to the throat, and 
taste and smell of cigarettes, which are often associated with the 
neurochemical effects of smoking, signals reward and becomes a cue 
to smoke. Exposure to tobacco advertising, particularly prevalent at 
point-of-sale retail and in popular media (e.g., movies, TV, and 
music), and exposure to others smoking can also elicit craving and 
smoking behavior (63–65).
Vulnerability to nicotine addiction
Not all smokers become regular, daily, or addicted users. The 
younger a person starts smoking cigarettes, the greater the risk of 
stronger physiological addiction to nicotine. Smoking co-occurs 
with mental illness and other addictive disorders, suggesting greater 
vulnerability, and research suggests the potential for a gateway 
effect. Genetic factors also influence the risk of nicotine dependence.
Adolescents and the developing brain. Nearly all (9 in 10) individuals 
who smoke started by the age of 18. Adolescence is a critical window 
for brain development, with the brain not reaching full maturity until 
the mid-20s. Adolescence is a period of enhanced neuroplasticity 
during which the underdeveloped neural networks necessary for 
adult-level judgment (the prefrontal cortical regions) cannot yet properly 
regulate impulses and emotion (66). As a consequence, adolescents 
are highly vulnerable to drug experimentation and addiction (67).
Nicotine exposure during adolescence may have lasting adverse 
consequences for brain development. In animals, nicotine exposure 
during adolescence produces permanent changes in brain structure 
and function, including enhanced self-administration of nicotine 
and other drugs as adults (68). In humans, adolescents experience 
symptoms of dependence at lower levels of nicotine exposure than 
adults (69, 70). Earlier onset of daily smoking is associated with 
higher nicotine dependence scores (71) and heavier and longer smoking 
careers compared to late-onset smokers (72, 73). Individuals who 
begin smoking as teens are more likely to become lifelong smokers 
than those who start smoking in their 20s or later (74–76). In a 
study of 1200 individuals, those who initiated smoking before age 
13 had the lowest likelihood of quitting, followed by those who 
initiated between ages 14 and 17, while adult initiators (18+) had 
the highest likelihood of quitting (77). A number of studies have 
yielded similar results (78). The findings have implications for policy 
interventions aimed at preventing initiation in youth.
Smoking among people with mental illness. Mental illness com-
monly co-occurs with tobacco addiction (79, 80), including major 
depression, bipolar disorder, posttraumatic stress disorder (PTSD), 
and schizophrenia. Evidence that nicotine may improve cognitive 
function and sensory gating and reduce psychotic symptoms has 
led to the self-medication hypothesis, which posits that people with 
psychiatric disorders smoke to lessen their symptoms (81). The 
tobacco industry funded research in support of the self-medication 
hypothesis (82). Bidirectional models maintain that smoking and 
psychiatric symptoms influence each other (83), and studies indicate 
that early-onset smoking may predispose to depression, anxiety 
disorders, and schizophrenia (80). There is also evidence of modest 
shared genetic susceptibility to tobacco dependence and mental 
illness.
Cigarette smoking induces the metabolism of some psychiatric 
medications leading to lower blood levels, with reduced sedation, and 
may explain, in part, the improvements observed in cognitive function 
(84). Studies in youth and adults, cross-sectional and prospective, have 
found that current smoking is predictive of future suicidal behavior— 
independent of depressive symptoms, previous suicidal acts, and 
other substance use—and that longer lifetime smoking (>40 years 
versus ≤10 years) is associated with a twofold higher odds of suicide 
(80). Notably, quitting smoking appears to mitigate the risk (85).
The self-medication hypothesis—that people smoke to manage 
their mental health symptoms—drove concerns that treating smoking 
would worsen mental health. This belief and the perceptions that 
smoking is a chronic, rather than acute, concern have been substan-
tial barriers to addressing tobacco use in psychiatric settings (86). 
Newer research, however, indicates that quitting smoking is associ-
ated with improvements in mental health, including reductions in 
depression, anxiety, psychotic symptoms, emotional lability, and PTSD 
symptoms (87–89). In a randomized trial with smokers recruited 
from inpatient psychiatry, the tobacco cessation intervention was 
associated with a significantly lower likelihood of rehospitalization 
out to 18-month follow-up (90). A meta-analysis of 26 longitudinal 
studies assessing mental health before smoking cessation and at least 
6 weeks after abstinence found reduced depression, anxiety, and stress 
and greater overall well-being compared with continuing to smoke 
(49). The effects were comparable for those with and without psy-
chiatric disorders. If people self-medicate nicotine for acute relief, 
it does not appear to produce sustained benefits and is a form of 
self-medication that should be discouraged.
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Smoking among people with other addictions. Three in four adults 
with alcohol use disorder and 9 in 10 adults with drug use disorders 
smoke tobacco (91). Early-onset smoking is a significant predictor 
of lifetime drinking, more excessive alcohol consumption, and the 
subsequent development of lifetime alcohol abuse and dependence 
(72). Nicotine addiction, in the form of cigarette smoking, causes 
greater morbidity and mortality than any other single drug addic-
tion and the combination of all other risks (92). Among individ-
uals treated for alcohol dependence, tobacco-related diseases were 
responsible for half of all deaths, greater than alcohol-related 
causes (93).
While the causal progression remains under debate, tobacco use 
has been implicated as a “gateway” to other drugs of abuse (94). 
Possible mechanisms include nicotine enhancing the rewarding 
effects of other drugs, nicotine reducing the negative effects of 
another drug (for example, less sedation with alcohol use), and shared 
genetic susceptibility. Mice given nicotine in their drinking water 
for a week had an increased response to cocaine; nicotine caused 
epigenetic changes in DNA, in particular, affecting expression of the 
FosB gene found related to addiction (95). In human adults, cocaine 
users who smoked cigarettes before starting cocaine had a two- to 
threefold greater likelihood of cocaine dependence compared to those 
who tried cocaine before smoking cigarettes and compared to those 
who never became regular smokers (95). The inference was that 
brain changes due to early exposure to nicotine made it more likely 
that the individuals would become addicted to cocaine.
While concomitant smoking and drug use are common, treating 
smoking may improve sobriety outcomes in the long term. A 
meta-analysis of randomized controlled tobacco cessation trials 
with smokers in treatment for substance use disorders found 
that tobacco cessation interventions were associated with a 25% 
increased likelihood of sobriety from alcohol and drugs relative 
to usual care (96).
Genetic factors. Genetic factors also influence the risk of nicotine 
dependence. The strongest genetic factor associated with nicotine 
dependence involves the CHRNA5 gene, which encodes the 5 nAChR 
subunit (43, 56). The rs16969968 single-nucleotide polymorphism 
on chromosome 15 is associated with greater risk of becoming de-
pendent, a lower likelihood of smoking cessation, and increased risk 
of lung cancer and COPD. The nAChR with a reduced function 
5 subunit is thought to result in less aversiveness to nicotine and 
greater nicotine intake and, therefore, greater dependence. The other 
major genetic risk factor for nicotine dependence is the CYP2A6 
gene, which is associated with the rate of nicotine metabolism and 
greater nicotine dependence including smoking more cigarettes per 
day, more rapid onset of withdrawal symptoms during abstinence, 
and lower quit rates (35, 97).
TREATING NICOTINE ADDICTION IN ADULTS, WITH A FOCUS 
ON CONVENTIONAL CIGARETTES
As discussed, tobacco dependence is characterized as a physiologi-
cal dependence (addiction to nicotine) and behavioral (or condi-
tioned) habit of using tobacco. Hence, for maximal effectiveness, as 
recommended by U.S. Clinical Practice Guidelines, tobacco depen-
dence treatment engages a multipronged approach (98). Addiction 
can be treated with FDA-approved medications for smoking cessa-
tion; the behavioral habit can be treated through counseling and 
behavior change programs, and policy interventions can promote 
smoke-free environments, discussed in the “Tobacco Control 
Population-Based and Policy Approaches” section.
Counseling and psychosocial treatments
Brief cessation advice
With 7 in 10 tobacco users seeing a healthcare provider in a given 
year, opportunities exist for brief cessation clinical advice. Treating 
smoking is relevant to all areas of medicine, and the evidence in 
support of brief clinical cessation advice is strong (99). The U.S. Pre-
ventive Services Task Force gives a “grade A” recommendation 
for clinician-delivered brief tobacco cessation interventions (100). 
Counseling by nonphysician health providers, including nurses (101), 
oral health professionals (102), and pharmacists (103), also increases 
quit rates.
The gold standard for brief cessation advice is the National 
Cancer Institute’s (NCI) 5A’s to (i) ask all patients about use of all 
forms of tobacco; (ii) advise tobacco users to quit; (iii) assess patient 
readiness to quit; (iv) assist in the quit attempt with counseling, 
medications, and referrals; and (v) arrange follow-up. The 5 A’s 
increase patient treatment engagement, quit attempts, and tobacco 
abstinence (104).
Recognizing time constraints in the clinical setting, an alternate 
approach with evidence is Ask-Advise-Refer (AAR), whereby clini-
cians ask about tobacco use, advise tobacco users to quit, and then 
refer patients to an outside entity for assistance and follow-up, such 
as a tobacco quitline (1-800-QUIT-NOW) (105, 106). Further 
adaptation is Ask-Advise-Connect (AAC), the distinction being that 
the referral is provided in the form of a direct connection, such as a 
fax or other electronic referral (107). Comparison of AAR to the 
5 A’s delivered in 68 dental clinics found comparable quit rates, and 
both approaches were better than usual care (106). Sustained quit 
rates at long-term follow-up, however, were under 4% in all three 
study arms. A recognized standard of care, brief provider advice is 
effective for engaging patients in treatment and supporting quitting 
(98); however, to further improve sustained abstinence rates, more 
intensive interventions are needed.
Intensive counseling
Clinical practice guidelines recommend intensive cessation coun-
seling offered in person, individually or in groups, in clinical, 
behavioral, or community settings for treating smoking (98). The 
counseling framework tends to be cognitive behavioral and motivational, 
although, increasingly, other clinical approaches (e.g., mindfulness, 
acceptance, and commitment therapy) are being incorporated. A 
systematic review of 49 randomized trials with some 19,000 partici-
pants concluded that intensive counseling only (without medica-
tions) delivered by a cessation counselor on a one-to-one basis was 
more effective than minimal contact (i.e., brief advice and self-help 
materials) and had greater effects when combined with cessation 
medications (108). Intensive individual and group counseling treat-
ments also have demonstrated effectiveness in workplace settings 
(109). Access to intensive counseling may be limited because of travel, 
time, cost, or privacy concerns. To overcome these barriers, tobacco 
quitlines were developed to improve accessibility and reach of 
tobacco cessation counseling treatment.
Tobacco quitlines
Tobacco quitlines are staffed by trained counselors or coaches who 
provide information, individual counseling, local referrals, self-help 
materials, and, in some cases, limited supplies of free cessation medi-
cations. The effectiveness of tobacco quitlines is well demonstrated 
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(110). Quitline services are available at no cost to U.S. residents 
and accessed via a toll-free national portal (1-800-QUIT-NOW or 
1-855-DÉJELO-YA), which links callers to their state quitline based 
on their area code. While specific services vary by state, by county, 
and over time, most state quitlines provide at least one counseling 
session to any adult tobacco user who calls, and many states provide 
a multi-call program that includes reactive and proactive calls. The 
reactive approach relies upon smokers to initiate the calls, whereas 
the proactive approach makes outbound calls to engage tobacco 
users. In meta-analyses, better outcomes are seen with multi-call 
versus single-call protocols (110) and with proactive versus reactive 
quitline services (111).
Although free, convenient, and confidential, quitlines in most 
states reach an average of only 1% of smokers annually (112). Even 
among smokers aware of quitlines and making a quit attempt, reach 
is only about 8% (113). The Centers for Disease Control and 
Prevention’s (CDC) Tips From Former Smokers (Tips) tobacco 
education campaign, developed to encourage quitting and raise 
awareness of state quitline services and conducted annually since 
2012, has generated hundreds of thousands of additional calls to 
state quitlines (114). The Tips campaign and its impact on quitting 
are discussed under media campaigns in the “Tobacco Control 
Population-Based and Policy Approaches” section. To further ex-
pand reach, some state quitlines have incorporated mobile health 
technologies.
Mobile technologies: Internet, text, and social
Mobile technologies, such as internet interventions, email, chat, 
and texting, are being leveraged for health promotion at a low cost, 
with broad reach potential and with evidence of efficacy.
Internet. Internet-delivered tobacco cessation interventions have 
existed for more than 25 years and have continued to develop in 
sophistication, level of interaction, and complexity of functionality, 
as well as treatment efficacy. In 2011, the Community Preventive 
Services Task Force deemed the evidence insufficient to recommend 
internet-based interventions for tobacco cessation (115). Two years 
later, a 2013 review concluded that internet-based interventions can 
assist in achieving long-term smoking cessation, particularly inter-
active programs tailored to the individual (116). A 2016 review noted 
significant improvements in internet-based smoking cessation in-
terventions with evidence of superior efficacy relative to print 
materials and equivalent efficacy to telephone and in-person counseling 
(117). Relative to quitlines, internet-delivered interventions have 
27 times greater national reach [annually, 11 million for internet 
versus 400,000 for quitlines (112)] and at a lower cost per quit [e.g., 
$291 for internet versus $900 for quitlines (118)].
A model example of an internet-delivered tobacco cessation 
program is NCI’s Smokefree.gov, which combines evidence-based 
guidelines for quitting smoking, tailored to readiness to quit, with 
availability of professional assistance via instant messaging and 
telephone (1-877-44U-QUIT). The site has also tailored offerings 
for veterans, women, adolescents, Spanish-speaking smokers, and 
older adults. SmokefreeTXT is an additional mobile service that 
provides encouragement, advice, and tips for young adults to quit 
smoking. Smokefree smartphone apps are offered to provide moti-
vational reminders and help with tracking progress with quitting 
smoking. The Smokefree.gov site had 3.6 million visitors in 2016 
(118) and received high user satisfaction ratings (119). Randomized 
trial evidence supports Smokefree.gov as a population-based in-
tervention for smoking cessation (118, 120).
Mobile technologies. Mobile phone–based tobacco cessation in-
terventions that send automated low-cost messages (i.e., texts) were 
deemed to have sufficient evidence of efficacy to be recommended 
by the Community Preventive Services Task Force (121). Trials in 
New Zealand and the United Kingdom evaluated text messages sent 
daily up to the quit day that tapered to a maintenance phase; texts 
included general information, motivational messages, quitting 
advice, and distraction strategies, and effects on quit rates were sig-
nificant relative to no-text controls (122, 123). A 2016 review found 
significant short-term effects of text-based smoking cessation inter-
ventions, although they were not sustained at long-term (>6 months) 
follow-up (124). Given the chronic, relapsing nature of nicotine 
addiction, more intensive extended interventions may be needed.
With the potential for more dynamic interactions, smoking 
cessation apps (applications) are available for download from digital 
marketplaces (e.g., iTunes and Google Play) for use on smartphones, 
tablets, and other handheld devices. A 2014 search identified 
546 smoking cessation apps in the Apple Store and on Google Play 
that were downloaded some 3.2 million times in the United States and 
20 million times worldwide (125). Broad reach and high scalability 
make apps particularly well suited for serving remote and resource- 
poor settings. Advantages include low or no cost to the user, self- 
tracking and tailored feedback functionalities, and use of images 
and video for enhanced health literacy. However, a 2015 review of 
225 Android apps for quitting smoking found that most provide 
simplistic tools (e.g., calculators and trackers); use of tailoring was limited, 
although positively related to app popularity and user ratings of quality 
(126). Evaluation of intervention effects on quitting smoking is 
sorely needed. Notably, one randomized trial found that a simpler, 
direct texting program outperformed a smoking cessation app (127).
Social media. Social media, such as Twitter and Facebook, are 
being explored for delivering cessation treatment. In the United 
States, 74% of online adults use social media, 80% of whom are 
seeking health information, and a majority access the sites daily 
(128). A promising technology, efforts to sustain engagement are 
key and can be challenging; like predecessor technologies such as 
bulletin boards and listservs, initial interest may be high but then 
tends to wane (129, 130). There is preliminary evidence, however, of 
good acceptability and efficacy. Using Twitter, small, private groups 
of 20 smokers, who interact for 100 days, have been studied. The 
intervention (Tweet2Quit) seeds the groups with twice-daily au-
tomessages to encourage group sharing and support. In a random-
ized trial, the Tweet2Quit Twitter groups added to Smokefree.gov 
and the nicotine patch fostered peer-to-peer support for quitting 
and significantly doubled the likelihood of reported sustained absti-
nence relative to the website and patch alone (131). Similar efforts 
are being developed on Facebook, with a focus on engaging young 
adults into cessation treatment. In a randomized trial, a novel 
Facebook smoking cessation intervention increased abstinence at 
the end of treatment, although effects were not sustained out to 
1-year follow-up (132).
Social media can provide varying degrees of anonymity, which 
may be attractive. Having tried and failed to quit smoking in the 
past, smokers may not initially publicize their quit attempts within 
their main social circle (133). With social media sites that are largely 
uncurated or expert moderated, however, users should be forewarned 
that inaccurate information may be posted. For example, online 
communities may encourage use of non–evidence-based treatments 
(e.g., laser, herbs, acupuncture, or hypnosis for quitting smoking) 
Prochaska and Benowitz, Sci. Adv. 2019; 5 : eaay9763     16 October 2019
S C I E N C E  A D V A N C E S  |  R E V I E W
9 of 23
(129). A heterogeneous group of emerging applications and knowl-
edge gaps remain concerning best strategies for maximizing the 
reach and efficacy of mobile technologies for treating nicotine 
addiction as well as the comparative effectiveness relative to in-person 
approaches.
Monetary incentives
Monetary incentives that reward outcome (i.e., quitting smoking) 
or engagement (e.g., treatment participation) have been evaluated 
in 33 trials, with a meta-analysis finding evidence of increased absti-
nence that persisted after the incentives ceased (134). The level of 
the incentives ranged from zero (self-deposits) to between $45 and 
$1185, with no clear direction of effect by level of incentive. Condi-
tional payments (i.e., payment for abstinence) outperformed non-
conditional payments. Findings from a subgroup analysis of eight 
trials conducted with smokers with substance use problems were 
consistent with the overall analysis. A summary of nine trials with 
pregnant smokers reported more than twofold greater odds of 
abstinence at longest follow-up assessment (up to 24 weeks post-
partum). The findings are particularly important given the substantial 
health harms of smoking to mother and baby and that, currently, 
there is no other effective cessation intervention for pregnant smokers.
Pharmacotherapies to aid smoking cessation
While counseling and psychosocial treatments help promote cessa-
tion, medications that address the neuropharmacological effects 
of nicotine and nicotine withdrawal further enhance the likelihood 
of quitting. E-cigarettes, which allow continued self-administration of 
nicotine without combustion, can also promote quitting smoking.
Smoking cessation guidelines, such as those from the U.S. Public 
Health Service and National Cancer Center Network, recommend 
smoking cessation medications for all daily smokers where feasible 
and safe (98, 135). Pharmacotherapy can be considered for nondaily 
smokers as well, although there are few clinical trials to guide treat-
ment in this group. The mechanism of benefit in nondaily smokers 
would be reduction of nicotine reward from cigarettes by nicotinic 
receptor desensitization or antagonism, as discussed below. Table 2 
presents the FDA-approved smoking cessation medications, in-
cluding dosing guidelines, advantages, disadvantages, adverse effects, 
and precautions. FDA-approved medications are NRT in the form 
of gum, patches, lozenge, nasal spray and inhaler, varenicline, and 
bupropion. Nicotine gums, lozenges, and patches are available over 
the counter in the United States, while the nicotine nasal spray, nic-
otine inhaler, varenicline, and bupropion are by prescription only. 
Nicotine mouth spray is available outside of the United States and 
has evidence of acceptability, efficacy, and safety, including with 
minimal behavioral support (136).
In general, medications serve to make smokers more comfortable 
while they learn to live and cope with daily cues/triggers and life 
stressors without smoking cigarettes. There are three main mecha-
nisms by which medications can facilitate smoking cessation: (i) 
reduction of nicotine withdrawal symptoms, (ii) reduction of the 
rewarding effects of nicotine from smoking by blocking or desensi-
tizing nicotine receptors, and (iii) providing an alternative source of 
nicotine with the desired pharmacologic effect previously provided 
by nicotine from cigarettes. NRT medications are not as satisfying 
as cigarette smoking because of slower absorption of nicotine; nico-
tine delivery from e-cigarettes can resemble that of a cigarette, and 
these devices tend to be much more satisfying. Most smoking cessa-
tion medications are recommended for 8 to 12 weeks, although use 
for 6 months or longer may be necessary to achieve optimal quit 
rates. It makes sense to use medications to support smoking cessa-
tion for as long as the individual feels at risk for relapse. For those 
switching to e-cigarettes as a less harmful substitute for cigarette 
smoking, use sometimes continues for many months or years.
Nicotine replacement therapy
Nicotine medications consist of purified nicotine that is adminis-
tered to ameliorate symptoms of physical dependence on nicotine. 
The particular actions of different products vary according to route of 
administration and rate of nicotine absorption into the bloodstream. 
For example, nicotine patches deliver nicotine slowly, relieving nico-
tine withdrawal symptoms and reducing positive effects of cigarette 
smoking, without providing much, if any, direct positive effects of 
nicotine. Nicotine gums, lozenges, sprays, and inhalers deliver nic-
otine more rapidly, providing some acute nicotine effects that may 
serve as a substitute for smoking a cigarette. Combining a short-acting 
(gum, lozenge, spray, or inhaler) with a long-acting (nicotine patch) 
NRT results in superior quit rates compared to any NRT product 
alone and is recommended as a first-line treatment (137).
NRT products are marketed in different strengths, with higher 
doses recommended for more dependent smokers based on the 
number of cigarettes smoked per day or time to first cigarette upon 
wakening. A 2019 Cochrane review concluded that 4-mg gum is 
more effective than 2-mg gum in more highly dependent smokers 
and that 21-mg patch is more effective than 14-mg patch in general 
(137). While clinical trials do not demonstrate superiority of 42- to 
21-mg dose nicotine patch, some clinicians do use high-dose patch 
for smokers with particularly severe withdrawal symptoms. Tapering 
of nicotine doses over time is an option for nicotine patches but does 
not appear to affect outcome in clinical trials.
All forms of NRT have shown similar efficacy in clinical trials 
(137), increasing quit rates by 50 to 100% compared to behavioral 
treatment alone. For the NRTs, compliance is greatest with nicotine 
patches, lower with gum and lozenge, and lowest with the nasal 
spray and inhaler. Nicotine patches are usually placed on the skin in 
the morning and deliver nicotine over 16 to 24 hours. Some smokers 
experience nicotine patch–related insomnia and/or abnormal dreams 
and do better removing the patch at bedtime. Use of patches for 
16 or 24 hours is equally effective in promoting quitting smoking. 
The pharmacokinetics of nicotine gum, lozenge, and inhaler are 
similar, with gradual absorption of relatively low doses of nicotine 
over 15 to 30 min. Use every 1 to 2 hours provides the best pharma-
cologic response. The nicotine inhaler is a plastic device inhaled like 
a cigarette but delivers nicotine to the oropharyngeal area rather 
than to the lungs, which explains its slow absorption. The main 
advantage of the inhaler is providing a hand-to-mouth experience 
similar to smoking. All oral nicotine products have an alkaline pH, 
which results in a high proportion of nicotine in the free base form, 
which is rapidly absorbed across mucous membranes. Acidic bever-
ages (e.g., coffee, citrus juice, sodas, and many alcohol beverages) 
reduce the pH and reduce nicotine absorption and should be avoided 
for >10 min before using oral NRT products. The nicotine nasal 
spray is absorbed much faster than the other rapid-release products, 
most closely resembling a cigarette. More dependent smokers may 
find nicotine nasal spray to be more effective than other NRT prod-
ucts for smoking cessation. The spray is associated with more local 
toxicity, including a burning sensation, watery eyes, and sneezing; 
however, tolerance develops to these effects with regular use of the 
spray over 1 to 2 days.
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Table 2. FDA-approved medications for smoking cessation.  
Nicotine Replacement Therapy (NRT) Formulations
Bupropion SR Varenicline
Gum Lozenge Transdermal Patch Nasal Spray Oral Inhaler
Product
Nicorette1, Generic
OTC 2 mg, 4 mg
original, cinnamon, 
fruit, mint
Nicorette1, Generic
Nicorette1 Mini OTC 
2 mg, 4 mg; 
cherry, mint
NicoDerm CQ1, 
Generic
OTC (NicoDerm 
CQ, generic)
7 mg, 14 mg, 21 mg 
(24-hr release)
Nicotrol NS2 Rx
Metered spray
10 mg/mL nicotine 
solution
Nicotrol Inhaler2 Rx
10 mg cartridge
 delivers 4 mg 
inhaled vapor
Zyban1, Generic Rx
150 mg sustained- 
release tablet
Chantix2
Rx 0.5 mg, 1 mg 
tablet
Precautions ▪Recent (≤ 2 weeks) 
myocardial 
infarction
▪Serious  
underlying 
arrhythmias
▪Serious or  
worsening  
angina pectoris
▪Temporomandibular 
joint disease
▪Pregnancy3 and 
breastfeeding
▪Adolescents  
(<18 years)
▪Recent (≤ 2 weeks) 
myocardial 
infarction
▪Serious underlying 
arrhythmias
▪Serious or 
worsening angina 
pectoris
▪Pregnancy3 and 
breastfeeding
▪Adolescents (<18 
years)
▪Recent (≤ 2 weeks) 
myocardial  
infarction
▪Serious underlying  
arrhythmias
▪Serious or 
worsening  
angina pectoris
▪Pregnancy3 and  
breastfeeding
▪Adolescents  
(<18 years)
▪Recent (≤ 2 weeks) 
myocardial  
infarction
▪Serious underlying 
arrhythmias
▪Serious or worsening 
angina pectoris
▪Underlying chronic  
nasal disorders 
(rhinitis, nasal  
polyps, sinusitis)
▪Severe reactive airway 
disease
▪Pregnancy3 and 
breastfeeding
▪Adolescents  
(<18 years)
▪Recent (≤ 2 weeks) 
myocardial infarction
▪Serious underlying 
arrhythmias
▪Serious or worsening 
angina pectoris
▪Bronchospastic disease
▪Pregnancy3 and 
breastfeeding
▪Adolescents (<18 years)
▪Concomitant therapy 
with medications/
conditions known to 
lower the  
seizure threshold
▪Hepatic impairment
▪Pregnancy3 and 
breastfeeding
▪Adolescents (<18 years)
▪Treatment-emergent 
neuropsychiatric  
symptoms4 Boxed  
warning removed 
12/2016
Contraindications:
▪Seizure disorder
▪Concomitant bupropion  
(e.g., Wellbutrin) 
therapy
▪Current or prior  
diagnosis of  
bulimia or  
anorexia nervosa
▪Simultaneous abrupt 
discontinuation of  
alcohol or sedatives/
benzodiazepines
▪MAO inhibitors in  
preceding 14 days; 
concurrent  
use of reversible  
MAO inhibitors
▪Severe renal 
impairment  
(dosage 
adjustment  
is necessary)
▪Pregnancy3 and  
breastfeeding
▪Adolescents (<18 years)
▪Treatment-emergent 
neuropsychiatric 
symptoms4
Boxed warning removed 
12/2016
Dosing 1st cigarette ≤30 
minutes after 
waking: 4 mg
1st cigarette >30 
minutes after 
waking: 2 mg
Weeks 1–6:
1 piece q 1–2 hours
Weeks 7–9:
1 piece q 2–4 hours
Weeks 10–12:
1 piece q 4–8 hours
▪Maximum,  
24 pieces/day
▪Chew each piece 
slowly
▪Park between cheek 
and gum when 
peppery or tingling 
sensation appears 
(~15–30 chews)
▪Resume chewing 
when tingle fades
▪Repeat chew/park 
steps until most of 
the nicotine is  
gone (tingle  
does not return; 
generally 30 min)
▪Park in different areas 
of mouth
▪No food or beverages 
15 minutes before 
or during use
▪Duration:  
up to 12 weeks
1st cigarette ≤30 
minutes after 
waking: 4 mg
1st cigarette >30 
minutes after 
waking: 2 mg
Weeks 1–6:
1 lozenge q 1–2 
hours
Weeks 7–9:
1 lozenge q 2–4 
hours
Weeks 10–12:
1 lozenge q 4–8 
hours
▪Maximum, 20 
lozenges/day
▪Allow to dissolve 
slowly (20–30 
minutes)
▪Nicotine release  
may cause a  
warm, tingling  
sensation
▪Do not chew or 
swallow
▪Occasionally  
rotate to  
different areas  
of the mouth
▪No food or 
beverages  
15 minutes  
before or  
during use
▪Duration:  
up to 12 weeks
>10 cigarettes/day:
21 mg/day x  
4–6 weeks
14 mg/day x 2 weeks
7 mg/day x 2 weeks
≤10 cigarettes/day:
14 mg/day x 6 weeks
7 mg/day x 2 weeks
▪Rotate patch  
application  
site daily; do  
not apply a  
new patch to  
the same skin  
site for at least  
one week
▪May wear patch  
for 16 hours  
if patient  
experiences 
sleep  
disturbances  
(remove at  
bedtime)
▪Duration:  
8–10 weeks
1–2 doses/hour
(8–40 doses/day)
One dose = 2 sprays  
(one in each nostril); 
each spray delivers  
0.5 mg of nicotine  
to the nasal mucosa
▪Maximum
−5 doses/hour or
−40 doses/day
▪For best results,  
initially use at  
least 8 doses/day
▪Do not sniff, swallow, 
or inhale through the 
nose as the spray is 
being administered
▪Duration: 3 months
6–16 cartridges/day 
Individualize dosing; 
initially use 1 
cartridge q 1–2 hours
▪Best effects with 
continuous puffing 
for 20 minutes
▪Initially use at least 6 
cartridges/day
▪Nicotine in cartridge is 
depleted after 20 
minutes of active 
puffing
▪Inhale into back of 
throat or puff in 
short breaths
▪Do NOT inhale into the 
lungs (like a 
cigarette) but “puff” 
as if lighting a pipe
▪Open cartridge retains 
potency for 24 hours
▪No food or beverages 
15 minutes before or 
during use
▪Duration: 3–6 months
150 mg po q AM x 3 days, 
then 150 mg po bid
▪Do not exceed  
300 mg/day
▪Begin therapy 1–2 
weeks prior to quit 
date
▪Allow at least 8 hours 
between doses
▪Avoid bedtime dosing to 
minimize insomnia
▪Dose tapering is  
not necessary
▪Duration: 7–12 weeks, 
with maintenance up 
to 6 months in 
selected patients
Days 1–3:  0.5 mg 
po q AM
Days 4–7:  0.5 mg 
po bid
Weeks 2–12:  1 mg  
po bid
▪Begin therapy  
1 week prior  
to quit date
▪Take dose after  
eating and with a  
full glass of water
▪Dose tapering  
is not necessary
▪Dosing adjustment  
is necessary for  
patients with 
severe  
renal impairment
▪Duration: 12 weeks;  
an additional 
12-week course 
may be used in 
selected patients
▪May initiate up to  
35 days before  
target quit date  
OR may reduce  
smoking over a  
12-week period  
of treatment 
prior  
to quitting and 
continue 
treatment for an 
additional  
12 weeks
continued on next page
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Overall, NRT products are well tolerated and present few safety 
concerns. Safety concerns with NRT are primarily skin irritation 
with patches, gastrointestinal symptoms with oral products, and 
nasal/throat burning and irritation with nasal spray. Nicotine’s car-
diovascular effects raised concern about NRT cardiovascular safety. 
Nicotine enhances sympathetic neural activity, resulting in increased 
heart rate, constriction of blood vessels, induction of proatherogenic 
lipid profiles (lower high-density lipoprotein cholesterol), develop-
ment of insulin resistance, and possible promotion of arrhythmias 
(138). Cigarette smoke delivers not only nicotine but also many ox-
idants, prothrombotic and other toxic chemicals, making smoking 
much more toxic than nicotine alone. Clinical trials and other stud-
ies of NRT in patients with cardiovascular disease find no increase 
in adverse cardiovascular events due to NRT (139, 140).
Nicotine Replacement Therapy (NRT) Formulations
Bupropion SR Varenicline
Gum Lozenge Transdermal Patch Nasal Spray Oral Inhaler
Adverse 
Effects
▪Mouth and throat 
irritation
▪Jaw muscle soreness
▪Hiccups
▪GI complaints 
(dyspepsia, nausea)
▪May stick to dental 
work
▪Mouth and throat 
irritation
▪Hiccups
▪GI complaints 
(dyspepsia, 
nausea)
▪Local skin reactions 
(erythema, 
pruritus, burning)
▪Sleep disturbances 
(abnormal or 
vivid dreams, 
insomnia); 
associated with 
nocturnal 
nicotine 
absorption
▪Nasal and/or throat 
irritation (hot, 
peppery, or burning 
sensation)
▪Ocular irritation/
tearing
▪Sneezing
▪Cough
▪Mouth and/or throat 
irritation
▪Cough
▪Hiccups
▪GI complaints 
(dyspepsia, nausea)
▪Insomnia
▪Dry mouth
▪Nausea
▪Anxiety/difficulty 
concentrating
▪Constipation
▪Tremor
▪Rash
▪Seizures (risk is 0.1%)
▪Neuropsychiatric 
symptoms (rare; see 
Precautions)
▪Nausea
▪Sleep disturbances 
(insomnia, 
abnormal/vivid 
dreams)
▪Headache
▪Flatulence
▪Constipation
▪Taste alteration
▪Neuropsychiatric 
symptoms (rare; 
see Precautions)
▪Adverse effects more commonly experienced 
when chewing the lozenge or using incorrect 
gum chewing technique (due to rapid 
nicotine release):
−Lightheadedness/dizziness
−Nausea/vomiting
−Hiccups
−Mouth and throat irritation
Advantages ▪Might serve as an oral 
substitute  
for tobacco
▪Might delay  
weight gain
▪Can be titrated to 
manage withdrawal 
symptoms
▪Can be used in 
combination with 
other agents  
to manage 
situational urges
▪Relatively inexpensive
▪Might serve as an 
oral substitute for 
tobacco
▪Might delay weight 
gain
▪Can be titrated to 
manage 
withdrawal 
symptoms
▪Can be used in 
combination with 
other agents to 
manage 
situational urges
▪Relatively 
inexpensive
▪Once-daily dosing 
associated with 
fewer adherence 
problems
▪Of all NRT products, 
its use is least 
obvious to others
▪Can be used in 
combination 
with other 
agents; delivers 
consistent 
nicotine levels 
over 24 hours
▪Relatively 
inexpensive
▪Can be titrated to 
rapidly manage 
withdrawal 
symptoms
▪Can be used in 
combination with 
other agents to 
manage situational 
urges
▪Might serve as an oral 
substitute for 
tobacco
▪Can be titrated to 
manage withdrawal 
symptoms
▪Mimics hand-to-mouth 
ritual of smoking
▪Can be used in 
combination with 
other agents to 
manage situational 
urges
▪Twice-daily oral dosing 
is simple and 
associated with fewer 
adherence problems
▪Might delay weight gain
▪Might be beneficial in 
patients with 
depression
▪Can be used in 
combination with 
NRT agents
▪Relatively inexpensive 
(generic formulations)
▪Twice-daily oral 
dosing is simple 
and associated 
with fewer 
adherence 
problems
▪Offers a different 
mechanism of 
action for 
patients who 
have failed other 
agents
▪Most effective 
cessation agent 
when used as 
monotherapy
Disadvantages ▪Need for frequent 
dosing can 
compromise 
adherence
▪Might be problematic 
for patients with 
significant dental 
work
▪Proper chewing 
technique is 
necessary for 
effectiveness and to 
minimize adverse 
effects
▪Gum chewing might 
not be acceptable or 
desirable for some 
patients
▪Need for frequent 
dosing can 
compromise 
adherence
▪Gastrointestinal side 
effects (nausea, 
hiccups, 
heartburn) might 
be bothersome
▪When used as 
monotherapy, 
cannot be 
titrated to 
acutely manage 
withdrawal 
symptoms
▪Not recommended 
for use by 
patients with 
dermatologic 
conditions (e.g., 
psoriasis, eczema, 
atopic dermatitis)
▪Need for frequent 
dosing can 
compromise 
adherence
▪Nasal administration 
might not be 
acceptable or 
desirable for some 
patients; nasal 
irritation often 
problematic
▪Not recommended for 
use by patients with 
chronic nasal 
disorders or severe 
reactive airway 
disease
▪Cost of treatment
▪Need for frequent 
dosing can 
compromise 
adherence
▪Cartridges might be 
less effective in cold 
environments 
(≤60°F)
▪Cost of treatment
▪Seizure risk is increased
▪Several 
contraindications and 
precautions preclude 
use in some patients 
(see Precautions)
▪Patients should be 
monitored for 
potential 
neuropsychiatric 
symptoms4 (see 
Precautions)
▪Patients should be 
monitored for 
potential 
neuropsychiatric 
symptoms4 (see 
Precautions)
▪Cost of treatment
Cost/day5 2 mg or 4 mg: 
$1.90–$3.60
(9 pieces)
2 mg or 4 mg: 
$3.33–$3.60
(9 pieces)
$1.52–$2.90
(1 patch)
$8.72
(8 doses)
$14.88
(6 cartridges)
$2.58–$8.25
(2 tablets)
$15.14
(2 tablets)
Abbreviations: MAO, monoamine oxidase; NRT, nicotine replacement therapy; OTC, over-the-counter (nonprescription product); Rx, prescription product.
For complete prescribing information and a comprehensive listing of warnings and precautions, please refer to the manufacturers’ package inserts.
Copyright © 1999-2019 The Regents of the University of California. All rights reserved. Updated January 9, 2019.
 1Marketed by GlaxoSmithKline.   2Marketed by Pfizer.   3The U.S. Clinical Practice Guideline states that pregnant smokers should be encouraged to quit without 
medication based on insufficient evidence of effectiveness and theoretical concerns with safety. Pregnant smokers should be offered behavioral counseling interventions 
that exceed minimal advice to quit.   4In July 2009, the FDA mandated that the prescribing information for all bupropion- and varenicline-containing products include a 
black-boxed warning highlighting the risk of serious neuropsychiatric symptoms, including changes in behavior, hostility, agitation, depressed mood, suicidal thoughts 
and behavior, and attempted suicide. Clinicians should advise patients to stop taking varenicline or bupropion SR and contact a health care provider immediately if they 
experience agitation, depressed mood, or any changes in behavior that are not typical of nicotine withdrawal, or if they experience suicidal thoughts or behavior. If 
treatment is stopped due to neuropsychiatric symptoms, patients should be monitored until the symptoms resolve. Based on results of a mandated clinical trial, the FDA 
removed this boxed warning in December 2016.   5Approximate cost based on the recommended initial dosing for each agent and the wholesale acquisition cost from 
Red Book Online. Thomson Reuters, December 2018.
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Varenicline
Varenicline is a partial agonist at the nicotinic 42 receptor, the 
major receptor mediating nicotine addiction. Varenicline both acti-
vates (about 50% of the maximal effect of nicotine) and blocks the 
effects of nicotine on the 42 receptor (141). The agonist effect serves 
to reduce withdrawal symptoms, while the antagonist effects reduce 
the rewarding effects of nicotine from cigarette smoke. Varenicline 
treatment before smoking cessation is often associated with reduced 
smoking, presumably because smoking is less satisfying, an effect 
that can promote subsequent cessation.
In clinical trials, varenicline is more effective than bupropion or 
nicotine patch in promoting smoking cessation and is comparably 
effective to combined NRT (142). The EAGLES trial, the largest 
smoking cessation trial conducted with 8000 smokers, directly com-
pared varenicline, bupropion, nicotine patch, and placebo. Varenicline 
outperformed all conditions; bupropion and nicotine patch were 
comparable to each other and were significantly better than placebo 
(143). EAGLES included smokers without and with psychiatric 
diagnoses. Quit rates were higher in those without psychiatric diag-
noses, but the relative efficacy of the various treatments was similar. 
Extended treatment with varenicline for 6 months is superior to the 
standard 12-week treatment and is recommended for smokers who 
feel at risk of relapse (144).
The most common adverse effect of varenicline is nausea, which 
is dose related and to which tolerance develops over time. Concern 
about nausea is the rationale for starting at lower doses (0.5 mg once 
to twice daily) for a week before starting the full dose (1.0 mg twice 
daily). Some smokers cannot tolerate the normal dose but do well 
on continued use of the lower dose. Anecdotal reports of neuropsy-
chiatric adverse effects of varenicline used for smoking cessation 
have been reported, prompting a black box warning in the label 
after the drug was marketed (for both varenicline and bupropion). 
The putative neuropsychiatric side effects included depression, psy-
chosis, and suicide, with potentially higher risk in smokers with 
psychiatric disease. However, the EAGLES trial found no evidence 
of increased neuropsychiatric adverse events for varenicline or 
bupropion relative to nicotine patch or placebo, in smokers with or 
without psychiatric illness, and in 2016, the black box warnings were 
removed for both varenicline and bupropion (143). Varenicline has 
been shown to enhance smoking cessation in patients with cardio-
vascular disease, including stable coronary heart disease and acute 
coronary syndrome (145, 146). Concern was raised about possible 
cardiovascular toxicity due to the nicotine-like effects of varenicline and 
anecdotal reports of adverse cardiovascular events, but several meta- 
analyses, a large retrospective cohort study, and clinical trials in smokers 
with cardiovascular disease, as well as the EAGLES trial, showed no 
increase in cardiovascular risk (147, 148). Varenicline has also been 
found efficacious for cessation of smokeless tobacco use (149).
Bupropion
Bupropion is a stimulant drug originally marketed as an antidepres-
sant. Bupropion blocks neuronal uptake of dopamine and norepi-
nephrine and has antagonist activity on the 42 nicotinic receptor. 
By blocking reuptake, bupropion increases brain levels of dopamine 
and norepinephrine, simulating effects of nicotine. Bupropion is 
marketed for smoking cessation as a sustained-release prepara-
tion. The drug works in both depressed and non-depressed smok-
ers. The usual duration of bupropion treatment is 12 weeks, 
but extended bupropion therapy for a year reduces relapse 
and enhances long-term quit rates (150). With lower quit rates, 
bupropion is considered to be second-line, after combination NRT 
and varenicline.
The main adverse effects of bupropion relate to its nervous sys-
tem stimulant actions. Some smokers are intolerant to bupropion 
because of anxiety, agitation, and insomnia. Bupropion reduces the 
seizure threshold and should not be used in smokers who are at risk 
for seizures. In overdose, bupropion causes tachycardia and hyper-
tension, but there is no evidence of increased cardiovascular events 
in smokers with preexisting stable cardiovascular disease (151, 152).
Combination pharmacotherapy
Combined NRT with patch and a more immediate acting product 
results in higher quit rates than single NRT [Cochrane meta-analysis: 
risk ratio (RR), 1.34; 95% confidence interval (CI), 1.18 to 1.48] 
(137). The combination of varenicline and nicotine patch has been 
evaluated with mixed results (153). The mechanism for why NRT 
should augment effects of varenicline is unclear, but the combina-
tion appears to be safe. The combination can be considered in a 
smoker who does not quit with dual NRT or varenicline. Bupropion 
in combination with nicotine patch or dual NRT increases quit 
rates compared to these drugs given alone (154). One trial reported 
promising results with the combination of varenicline and bupropion, 
although neuropsychiatric adverse effects were greater in the first 
2 weeks compared to varenicline alone (155).
Preloading pharmacotherapy
Many smokers would like to quit but are not prepared to commit to 
a quit date when seen by a healthcare provider. Starting pharmaco-
therapy while the smoker is still smoking with the expectation that 
quitting will be easier at a later date has been studied with the use of 
nicotine patches and varenicline. The pharmacological basis for this 
approach is that NRT, by desensitizing nicotinic receptors and 
reducing withdrawal symptoms between cigarettes, and varenicline, 
by antagonizing effects of nicotine from cigarettes and also provid-
ing relief of withdrawal symptoms, will reduce satisfaction from 
smoking and decrease the number of cigarettes smoked per day. 
Preloading trials with nicotine patches have shown mixed benefit 
on quitting with a weak overall effect, although some trials showed 
large beneficial effects (156, 157). Varenicline trials have shown 
benefit with a flexible quit date, and this approach is approved by 
the FDA (158). The attraction of precessation pharmacotherapy is 
that the clinician can now approach every patient who smokes, 
regardless of whether they are prepared to quit at the time of the 
visit, with a pharmacological intervention along with communica-
tion that this will help with quitting smoking in time, just as the 
clinician would advise every patient with hypertension to take med-
ication to prevent future disease. In this regard, a small trial involving 
heavy smokers with COPD, who were initially unprepared to quit, 
prescribed varenicline for as long as they wanted, without a fixed 
quit date, and by 18 months, most had quit (159).
Gradual reduction
Meta-analysis finds similar quit rates for gradual reduction in ciga-
rettes smoked per day before quitting as compared to abrupt quit-
ting (160). Even in trials that found that abrupt quitting resulted in 
higher quit rates, many in the gradual reduction group successfully 
quit. Precessation varenicline with instructions to reduce cigarettes 
per day by 50% at 4 weeks, 75% at 8 weeks, and completely quit at 
12 weeks showed substantial benefit compared to placebo (161).
Targeted pharmacotherapy
Personalized medicine aims to use individual patient characteristics to 
select the most effective and/or safest medications for their medical 
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problem. With long-term quit rates of 30% or less in most smoking 
cessation trials, there is interest in individualizing treatment to en-
hance efficacy. A promising approach involves phenotyping based 
on an individual rate of nicotine metabolism. Rapid metabolizers of 
nicotine, on average, smoke more cigarettes and take in more nicotine 
per day compared to slower metabolizers, presumably to maintain 
desired levels of nicotine in the body (35). Rapid metabolizers also 
have more severe withdrawal symptoms when not smoking (97). The 
nicotine metabolite ratio is a phenotypic marker of the rate of nico-
tine metabolism, which can be measured in blood, saliva, or urine 
(162, 163). In a prospective clinical trial, smokers were stratified as 
slow or normal metabolizers and treated with nicotine patch, 
varenicline, or placebo. In slow metabolizers, varenicline and nico-
tine patch were equally effective [odds ratio (OR), 1.13; P = 0.56], 
but in rapid metabolizers, varenicline was more effective (OR, 2.17; 
P < 0.001) (164). Side effects were greater for varenicline in slow 
metabolizers. The results indicate that slow metabolizers can be 
successfully treated with nicotine patch, at lower cost and with 
fewer side effects, but normal metabolizers are better treated with 
varenicline. More research is needed for confirmation.
Cytisine
Cytisine is an alkaloid extracted from the seeds of Cytisus laburnum, 
commonly known as golden chain or golden rain, a common 
garden plant in central and southern Europe. Cytisine has been 
used for smoking cessation in eastern and central European coun-
tries for more than 50 years. Cytisine, like varenicline, is a partial 
agonist at the 42 nAChR. Thus, it has nicotine-like effects, while 
at the same time it desensitizes and/or blocks the effects of nicotine 
from tobacco on the 42 nAChR. The recommended treatment 
regimen involves tapering doses over 25 days, a treatment course 
that is shorter than the 12 weeks recommended for most other 
smoking cessation medications, with significant effects relative to 
placebo (meta-analysis; RR, 1.74; 95% CI, 1.38 to 2.19) (165). The 
cost of cytisine in Europe is several-fold less than that of other 
smoking cessation medications. The drug is well tolerated, with the 
most common side effects being nausea, vomiting, dyspepsia, and 
dry mouth. Clinical trials of cytisine for FDA-approved use in the 
United States are underway.
Second-line smoking cessation medications
While not approved by the FDA, nortriptyline and clonidine have 
demonstrated efficacy in clinical trials for smoking cessation (166, 167). 
These drugs are used primarily by smoking cessation specialists for 
patients who have not responded to other treatment. Nortriptyline 
is a tricyclic antidepressant that blocks neuronal reuptake of nor-
epinephrine, thereby increasing levels of the neurotransmitter in 
the brain. These actions simulate some of the actions of nicotine on 
brain neurotransmitters. Clonidine is a central 2 adrenergic recep-
tor agonist that reduces sympathetic activity, resulting in sedation 
and anxiolysis. The benefit of clonidine is thought to be mediated 
by its anxiolytic and calming effects and appears to be most useful 
in smokers with anxiety as a major withdrawal symptom.
Smoking cessation pharmacotherapies in development or that 
have failed
A number of medications have been considered as possible candi-
dates for smoking cessation (168). While animal and/or small studies 
in people show effects on nicotine reward or smoking behavior, 
none of these medications alone has been shown in adequately sized 
clinical trials to be effective in promoting cessation, including (i) 
serotonin agonists (lorcaserin), (ii) acetylcholinesterase inhibitors 
(galantamine and rivastigmine), (iii) drugs affecting GABA recep-
tors (baclofen, topiramate, and gabapentin), and (iv) N-methyl-d- 
aspartate (NMDA) receptor modulators (cycloserine, memantine, 
and N-acetylcysteine).
A promising new medication is lorcaserin, a selective 
5- hydroxytryptamine 2c receptor agonist. The drug induces food 
satiety by increasing pro-opiomelanocortin production in the hypo-
thalamus and is FDA approved for weight loss in overweight 
individuals. Lorcaserin has also been reported to reduce nicotine 
self-administration in rodents. Because weight gain after stopping 
smoking is common and sometimes triggers relapse, lorcaserin alone 
or in combination with other smoking cessation medications has 
been of interest. In a placebo-controlled trial combining lorcaserin 
(10 mg twice daily) with varenicline, the combination significantly 
increased 3-month continuous abstinence (OR, 3.0; 95% CI, 1.5 to 
6.2) versus placebo (169), and weight gain was significantly less.
Medications evaluated in clinical trials and judged ineffective 
for quitting smoking include mecamylamine, serotonin-specific 
uptake inhibitors, anxiolytics (benzodiazepines and buspirone), 
MAO inhibitors (moclobemide and selegiline), modafenil, naltrexone, 
rimonabant, silver acetate, ondansetron, lobeline, nicotine vac-
cines, and Nicobrevin (quinine, methyl valerate, camphor, and 
eucalyptus oil).
E-cigarettes
A general discussion of e-cigarettes and other tobacco products for 
harm reduction, including consideration of benefits versus risks, is 
presented in the “Discussion: What Evidence Is Needed” section. 
Here, we specifically discuss evidence regarding e-cigarettes for 
smoking cessation. To date, no e-cigarette company has undergone 
FDA review and approval for use of e-cigarettes as a therapeutic aid 
for quitting smoking. Less than a handful of randomized controlled 
trials of e-cigarettes for smoking cessation have been published, and 
none has been conducted in the United States; hence, most of the 
evidence to date is observational.
E-cigarettes produce an aerosol from a liquid that typically con-
tains nicotine. The e-cigarette concept is to deliver nicotine by an 
inhaled route without generating products of tobacco combustion. 
NRT medications can aid cessation as discussed previously, but 
most smokers do not find NRT very satisfying, and quit rates are 
modest. The performance of e-cigarettes as nicotine delivery devices 
has evolved over time. The earliest devices looked like cigarettes but 
delivered very low levels of nicotine. The two clinical trials per-
formed with these devices were encouraging, but the quality of evi-
dence was low (170). Recently, a randomized clinical trial with 
886 smokers treated in the United Kingdom’s National Health Service 
evaluated a second-generation e-cigarette refillable tank–type device 
to patients’ choice of NRT provided free of cost for up to 3 months 
(171). All received standard behavioral support. At 1 year, the sus-
tained abstinence rate in the e-cigarette group was twofold greater 
than the NRT group (RR, 1.83; CI, 1.30 to 2.58). Among participants 
randomized to the e-cigarette arm who quit smoking, 80% were still 
using e-cigarettes at 1 year; in comparison, among those random-
ized to the NRT arm, continued use of NRT was 9% for those who 
quit smoking. While e-cigarettes were found to significantly increase 
smoking cessation, some have expressed concern about the unknown 
health risks of long-term e-cigarette use. Adverse effects reported 
during the trial included greater throat or mouth irritation in the 
e-cigarette group and more nausea in the NRT group. Overall, 
adverse effects were minor in severity.
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Population-based observational studies report different results 
depending on the intention of the smokers to quit, how e-cigarettes 
are used, and where the study was conducted. A four-country com-
parison found the likelihood of quitting with e-cigarettes to differ 
by the regulatory environment (172). In Canada and Australia, which 
have more restrictive e-cigarette regulations, e-cigarette use was 
associated with a significantly lower likelihood of quitting smoking 
relative to unassisted quitting (i.e., no medication or e-cigarette use), 
whereas in the United States and United Kingdom, which have less 
restrictive e-cigarette regulatory environments, e-cigarette use was 
associated with increased quitting, consistent with other reports 
(173, 174). The United Kingdom estimates that, annually, 22,000 to 
57,000 long-term cigarette quitters are associated with e-cigarette 
use, more than quits attributed to NRT or other forms of pharma-
cotherapy (175). In the United States and United Kingdom, daily 
use of e-cigarettes is associated with a greater likelihood of quitting 
smoking than nondaily use (176, 177). In a study from France, 
e-cigarette use was associated with not only higher smoking cessation 
rates but also greater relapse to smoking (178).
In conclusion, with respect to e-cigarettes, there is evidence 
that e-cigarettes can aid smoking cessation. This can occur both 
in the general population, where e-cigarette use is adopted as an 
acceptable and safer alternative to cigarette smoking, and in the 
context of a health service. The risks of long-term e-cigarette use 
are still unknown, and some medical professionals oppose the 
use of e-cigarettes for that reason. As discussed in the “Discussion: 
What Evidence Is Needed” section, there are also concerns about 
the use of e-cigarettes by children possibly creating a new epidemic 
of primary nicotine addiction, leading some U.S. public health 
professionals to conclude that the potential benefits of e-cigarettes 
for smoking cessation in adults are outweighed by the risks to 
youth.
TOBACCO CONTROL POPULATION-BASED AND POLICY 
APPROACHES
U.S. population-based and policy approaches successful for tobacco 
control include mass media tobacco education campaigns, expanded 
healthcare coverage for tobacco cessation treatment, excise taxation 
on tobacco products, clean air laws, and Tobacco 21 policies, which 
raise the minimum legal age to purchase tobacco products to age 21 
(92). Other population-based interventions to reduce tobacco use 
have faced challenges in the United States at the federal level (e.g., 
pictorial warnings on products, regulation of advertising, and pro-
motion at point of sale), and even state tobacco taxes and clean air 
laws have slowed (179, 180). In contrast, interventions in the tobacco 
retail environment are increasing rapidly at the local level (181). 
Also gaining traction at the FDA, and discussed in the “Discussion: 
What Evidence Is Needed” section, is an effort to reduce the amount 
of nicotine in combusted tobacco products to reduce its addictive 
effects.
Mass media tobacco education campaigns
An important component of comprehensive tobacco control pro-
grams, mass media tobacco education campaigns are composed of 
paid and earned media on TV, radio, community placements (e.g., 
billboards and bus shelters), magazines, newspapers, and digital/
social media platforms. Well-designed mass media campaigns 
implemented with sufficient reach, intensity, and duration can help 
counter pro-tobacco marketing, build support for tobacco control 
policies, increase awareness of tobacco’s harmful effects, promote 
quitting, and reduce smoking prevalence (182). Here, we describe the 
success of two ongoing U.S. campaigns.
Tips from former smokers
The CDC’s Tips national mass media tobacco education campaign 
has been implemented annually since 2012. Tips profiles real people 
living with serious long-term health consequences from smoking 
and secondhand smoke exposure based on evidence that messages 
graphically depicting the physical consequences of smoking-related 
diseases can encourage quit attempts (182, 183). While Tips primarily 
targets adult smokers, secondary audiences include family members, 
healthcare providers, and faith communities able to reach people 
who smoke. Campaign goals include building public awareness of 
tobacco’s harms to self and others, encouraging smokers to quit, and 
making free help available (e.g., national quitline). Tips has been 
effective at increasing population-level quit intentions, quit attempts, 
and sustained quits, with effectiveness persisting over time (184). 
In 2016, Tips ads featured Rebecca, a former smoker with depres-
sion. In a national evaluation, greater exposure to the Rebecca ads 
was associated with a greater likelihood of intending to quit and 
with making a quit attempt specifically among smokers with mental 
health conditions (185). National media campaigns are an important 
population-level strategy for reaching specific population groups, 
such as people living with mental health conditions, who are expe-
riencing tobacco-related disparities.
Real cost
The FDA’s Real Cost campaign is a national tobacco education cam-
paign aimed at preventing tobacco initiation and established tobacco 
use in youth ages 12 to 17. The campaign is disseminated on national 
TV and radio, via the internet/social media, in magazines and movie 
theaters, and on posters distributed to schools. The Real Cost’s cen-
tral theme in 2014–2016 was “Every cigarette costs you something,” 
with attention to teen-relevant concerns (e.g., cosmetic effects, loss 
of control, and toxic chemicals). Between 2014 and 2016, the Real 
Cost campaign estimated that 350,000 fewer adolescents initiated 
cigarette smoking (186). This time period was also when e-cigarettes 
surpassed combustible cigarettes in popularity among U.S. youth. 
In 2018, the Real Cost campaign shifted to a focus on e-cigarette 
prevention in youth.
Tobacco taxes
In the United States, tobacco tax increases have produced the desired 
effects of both dissuading young people from starting to smoke and 
encouraging smokers of all ages to quit, with the Community 
Preventive Services Task Force deeming the evidence strong (187). 
Given limited resources, at some point, the health, financial, and 
social costs of smoking outweigh the perceived benefits or drive of 
the addiction. Increasing tobacco taxes is suggested as a population- 
level strategy for reducing smoking among individuals with alco-
hol, drug, and mental health disorders (188). With tobacco tax 
increases should be the availability and promotion of cessation 
treatments via insurance coverage and resources such as the state 
quitlines.
Healthcare coverage for tobacco cessation treatments
Healthcare reform legislation can increase receipt of tobacco cessa-
tion treatment for smokers from disparity groups. The U.S. Affordable 
Care Act (ACA) mandated comprehensive coverage for tobacco 
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treatment for most private health plans and newly eligible Medicaid 
beneficiaries in states that expanded Medicaid, including at least 
two tobacco cessation attempts per year and four tobacco cessation 
counseling sessions (each 10+ min long) and prohibited cost-sharing 
and previous authorization restrictions for FDA-approved tobacco 
cessation medication. The ACA also removed coverage limits and 
preexisting condition exclusions. Concerning, however, was the 
ACA’s allowance for states to decide whether employers could charge 
smokers up to 50% more in premiums. Several states rejected the 
surcharge outright, while other states capped the maximum penalty 
at a lower level. National data from 2011 to 2014 indicate that in the 
first year of implementation, penalized smokers were less likely 
to be insured and the penalty did not encourage cessation (189). 
Charging smokers higher insurance premiums could discourage 
getting health insurance or lead to concealment of one’s smoking 
status; either would reduce opportunities for treatment. Tobacco 
cessation treatments are cost effective. In Massachusetts, for every 
$1 spent on cessation services for state Medicaid program beneficiaries, 
more than $3 was saved (190).
Smoke-free air
The Community Preventive Services Task Force deemed smoke-
free air policies to have strong evidence for reducing youth initi-
ation of tobacco use, increasing quitting among smokers, reducing 
exposure to secondhand smoke, reducing tobacco-related mor-
bidity and mortality, and reducing healthcare costs (191). Fur-
thermore, smoke-free policies do not adversely affect businesses. 
Smoke-free air policies in the home similarly reduce harmful 
secondhand smoke exposure, increase quit attempts and absti-
nence, and decrease cigarette consumption in adult smokers (192). 
A U.S. study found that statewide smoking bans in restaurants 
and bars were associated with reduced smoking among those 
with psychiatric conditions (193). Psychiatric facilities are in-
creasingly adopting smoking bans, although still not mandated 
nationally.
Tobacco 21 legislation
Given that few people start smoking after age 20 and that brain 
development continues through the mid-20s, with early drug 
exposure predictive of greater likelihood of chronic, addictive use, 
legislation has sought to raise the minimum tobacco sales age to 21 
(i.e., Tobacco 21). The Institute of Medicine concluded, based on 
simulation models, that Tobacco 21 laws would reduce smoking 
and related mortality (194). Lacking a federal Tobacco 21 law, states 
and local jurisdictions have passed legislation, with regional differ-
ences in coverage. As of January 2019, most U.S. residents aged 18 
to 20 were not covered by a Tobacco 21 policy, with the largest gaps 
in coverage in the South (195). As of 1 June 2019, 14 states and >400 
local jurisdictions have passed Tobacco 21 legislation; 16 of the 
non-adopting states preempt lower levels of government from 
implementing these regulations. Analyzing national data, a recent 
study found that Tobacco 21 policies were associated with a signifi-
cant absolute 3% reduction in the prevalence of smoking among 
18 to 20 year olds (196). Surveys indicate that two-thirds to three- 
quarters of U.S. adults are in favor of raising the minimum age of 
tobacco sales to 21 (197, 198).
Tobacco retailer restrictions
Tobacco products are readily accessible for open sale in retail 
outlets throughout the United States and globally. In the United 
States, there are an estimated 375,000 tobacco retailers (199); this 
equates to 27 tobacco retail locations for every McDonald’s restau-
rant. The tobacco retail environment contributes to tobacco-related 
disparities. Tobacco retailers concentrate disproportionately in 
disadvantaged areas (200). Even after adjusting for the density of 
retailers, cigarettes and little cigars/cigarillos cost less in these areas. 
The same is true for areas with a higher proportion of African 
American residents (201).
In its blueprint to end the U.S. tobacco epidemic, the Institute 
of Medicine recommended that governments develop, implement, 
and evaluate legal mechanisms for restructuring retail tobacco sales 
and restricting the number of tobacco outlets (202). In response, 
there has been a rapid rise in planning and implementation of retail 
interventions by states and communities (181). For example, at least 
two states and >200 localities restrict the sale of flavored tobacco 
(45 communities restrict the sale of menthol cigarettes); dozens 
have set a minimum price and pack size for little cigars/cigarillos, 
and at least three prohibit price discounts and coupon redemption 
(203). By restricting the sales and distribution of tobacco, the long-
term goal of these interventions is to reduce tobacco use and ineq-
uities in the retail environment. With a focus on youth, a global 
study of bans on tobacco point-of-sale ads in retail environments 
reported lower odds of ever smoking, lower smoking prevalence, 
and less daily smoking (204). A growing evidence base is informing 
best practices for state and local programs aimed at countering 
tobacco industry influence at the point of sale.
DISCUSSION: WHAT EVIDENCE IS NEEDED
Tobacco use remains the leading preventable cause of death in the 
United States and worldwide. While important public health gains 
have been achieved in reducing the prevalence of cigarette smoking, 
because of population growth and diversification of product, the 
absolute number of tobacco users in the United States has stayed 
relatively constant over the last 50 years, at about 40 million. 
Furthermore, dual use of tobacco products is on the rise (21, 22), 
and declines in smoking have not been equitable for all groups. 
Disproportionately affected by tobacco-related morbidity and 
mortality are people of certain racial/ethnic groups (e.g., African 
Americans and American Indian/Alaska Native people), individuals 
of lower income and lower education, and people with mental 
illness and substance use disorders.
Among adolescents, cigarette smoking has declined to under 
10%; however, the use of e-cigarettes has increased markedly, with 
27.5% of high school students reporting past 30-day use. Today, 
more young people in the United States are exposing their brains to 
nicotine than in recent years. Although free of the toxins from 
combustion, e-cigarettes typically still contain nicotine, the main 
psychoactive and addictive component in tobacco.
Our review covered evidence-based methods to treat smoking in 
adults and policy approaches to prevent nicotine product use in 
youth. The smoking cessation treatments with evidence in adults 
include seven FDA-approved cessation medications (Table 2), indi-
vidual and group counseling, quitlines and other mobile technologies, 
and monetary incentives. At the population level, mass media edu-
cation campaigns, product regulations, health insurance coverage 
of cessation treatments, and enactment of tobacco control policies 
(e.g., clean air, Tobacco 21, flavor bans, and retailer density restric-
tions) are promising interventions. Most efficacious are combinations 
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of medication and behavioral treatments leveraged in an environ-
ment with strong tobacco control policies. Notably absent are 
evidence-based treatments for stopping e-cigarette use, particularly 
in adolescents, an area of public health interest.
The changing marketplace and the challenges of treating addiction 
necessitate the sustained efforts of clinical providers, policymakers, 
and researchers. Investment in comprehensive tobacco cessation 
treatment at the state and federal levels and continued research in 
the development of novel behavioral and medication treatments, 
diagnostics for personalized medicine, technological innovations 
for broader reach, and evidence-based policies are warranted. Here, 
we briefly highlight some areas for further investigation.
Candidate new mechanisms of action for  
cessation pharmacotherapy
As reviewed above, existing medications aid in smoking cessation, 
but none has high success rates during a single course of treatment. 
As we learn more about the effects of nicotine on the brain and the 
mechanisms of addiction, we may gain insight into new molecular 
targets for nicotine addiction. In addition, combinations of treat-
ments with different actions, as exemplified by varenicline plus 
lorcaserin to both promote quitting and prevent associated weight 
gain, need to be explored.
Long-term effects of alternative/harm reduction products
The potential harms to health from various harm reduction 
products could not be extensively discussed here, but assessment of 
harm is a critical component of a reasoned benefit versus risk analysis. 
On the basis of current evidence, it is believed that e-cigarettes and 
heated tobacco will be very much less harmful than cigarette smoking, 
but how much less harmful is unknown. Heated tobacco products 
have been successfully marketed in Japan where 4.7% of the popu-
lation used the products in 2017, although 72% of heated tobacco 
users also continued to smoke cigarettes (205). The prevalence of 
cigarette smoking has declined substantially in recent years in Japan, 
and although speculated that heated tobacco use is responsible for 
that decline, this is unproven. Heated tobacco products are marketed 
in many other countries and are approved for use in the United 
States, but so far, uptake has been limited. As yet, there are no data 
on abuse liability and no trials of heated tobacco for combustible 
cigarette cessation, and we are unaware of any data on youth uptake 
of IQOS.
Considerable national and international debate has also occurred 
regarding the use of smokeless tobacco for harm reduction (206, 207). 
While the use of some forms of smokeless tobacco is associated with 
oral, esophageal, and pancreatic cancer and other adverse health 
effects, low nitrosamine smokeless tobacco is associated with much 
lower risk (208, 209). In Sweden, snus (ground tobacco in a teabag- 
like pouch placed between lip and gum) is manufactured and 
marketed under strict quality standards, resulting in low levels of 
nitrosamines (potential carcinogens) (210). In Sweden, 20% of men 
and 8% of women use snus, while the smoking prevalence is lower 
than in other countries. The incidence and mortality from smoking- 
related diseases is significantly lower in Sweden than in other Euro-
pean countries (211). Epidemiologic studies indicate that the health 
risks of Swedish snus use are low, including a small, if any, increase 
in cancer and cardiovascular disease risk and no increased risk of 
lung disease. On the basis of these observations, some public health 
experts advocate that smokeless tobacco be encouraged as an alter-
native to cigarette smoking. The potential harm reduction benefit of 
smokeless tobacco most likely varies by country and cultural norms. 
In Sweden, there is a long tradition of smokeless tobacco use, and 
most men use snus without a transition to cigarette smoking. However, 
in the United States, where smokeless tobacco use is much less 
widely accepted, there is concern that smokeless tobacco use is a 
gateway to smoking among youth (212). There is also concern that 
smokeless tobacco could reduce smoking cessation in dual users, 
because smokeless tobacco could be used in circumstances where 
smoking is prohibited. Controlled clinical trials of smokeless tobacco 
as an approach to aid smoking cessation or in switching from ciga-
rettes to smokeless tobacco have shown modest benefits, similar to 
NRT (213, 214).
Further mechanistic and epidemiologic studies are needed to 
help inform harm reduction public policy. In addition, likely an area 
of research development and interest in the very near future are 
study of cessation treatments for those users who want to quit their 
e-cigarette, heated tobacco, or snus use. Given the mechanism of 
nicotine addiction, it would seem reasonable that medications helpful 
in quitting smoking would prove efficacious; however, no random-
ized controlled trial to address these questions has been conducted 
to date.
Understanding and treating dual tobacco use
As mentioned at the start, dual use of tobacco products is on the rise 
(21, 22), and rates of dual use are threefold greater for high school 
students (11%) (13) than adults (3.7%) (11), with smoking ciga-
rettes and vaping e-cigarettes the most common combination. 
Analysis of survey data from the United States, United Kingdom, 
Canada, and Australia concluded that adults who smoke cigarettes 
and e-cigarettes concurrently should be considered a distinct group 
given higher levels of nicotine dependence and generally more 
pro-attitudes toward both smoking and vaping (215). Dual use may 
represent greater dependence and compulsion to dose nicotine in 
settings where smoking is prohibited or may reflect motivation to 
quit combustible cigarettes (23). In a nationally representative study, 
interest in quitting and attempts to quit were comparable among 
dual tobacco–using adults and cigarette-only users (216). The re-
search on dual tobacco use is still nascent. Greater and more detailed 
study is needed to understand use patterns of two or more tobacco 
products; the implication of different types of combinations; and 
the relationship of dual use to addiction, biomarkers of harm, and 
success with quitting.
Tobacco-drug co-use and translational potential
Treatment studies of cannabis use disorder in adults suggest that 
about half of participants also currently smoke tobacco. Among 
adolescents (217, 218) and adults (219), persistent tobacco use is 
associated with poorer treatment outcomes for cannabis use disor-
ders, and individuals who use both cannabis and tobacco in combi-
nation have higher rates of psychiatric and psychosocial problems 
as compared to individuals who smoke cannabis only (219). Blunt 
smoking (i.e., cannabis smoked in a cigar shell) is associated with 
greater difficulty controlling cannabis use (220) and high levels of 
toxicant exposures (e.g., carbon monoxide and carcinogens) (221), 
as compared to joint smoking. Despite decades of research on 
cannabis and tobacco use separately, there is little treatment research 
addressing the co-use of cannabis and tobacco. In addition, 
although currently the co-use of cannabis and nicotine by vaping is 
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relatively rare and primarily occurs among established tobacco or 
cannabis users, given the growth in popularity of both cannabis and 
nicotine vaping, it is likely to increase and expand to tobacco/ 
cannabis naïve individuals. Study of the behavioral co-use patterns 
and pharmacologic effects, with an understanding of addiction 
potential and quantified toxicant exposures, and the potential for 
pulmonary injury is needed.
There is a high concordance of tobacco use with virtually all other 
drugs of abuse, including cannabis, alcohol, opiates, and stimulants. 
Neurobiology research has found interacting neural circuits between 
nicotine and other abused substances. Such research may lead to 
discovery of medications that simultaneously treat multiple drugs 
of abuse. Likewise, studies of the genetics of addiction to nicotine 
and other substances of abuse, as well as genetic signals of concor-
dance of nicotine addiction with other addictions and mental ill-
nesses, may lead to the discovery of similar therapeutic targets.
Vulnerable populations
Smoking cessation treatment has been particularly challenging in 
some populations, including among people with mental illness, those 
with other substance use disorders, adolescents, pregnant smokers, 
and light and nondaily smokers. In addition, cessation success 
varies by race and ethnicity, as seen with lower quit rates in African 
American and American Indian/Alaska Native smokers. State data 
from Alaska indicate that the proportion of people who have quit 
smoking among those who have ever smoked (i.e., the quit ratio) is 
41% for Alaska Native adults compared to 62% for Alaskan adults 
of other races/ethnicities (222). This means that for the Alaska 
Native community, there are more current than former smokers. 
Behavioral interventions that are culturally relevant for specific 
populations and individualized pharmacotherapy approaches are 
needed. As an example, with funding from the National Heart, 
Lung, and Blood Institute (NHLBI), our research is testing the 
efficacy of internet-assisted tobacco cessation counseling in the 
remote region of Norton Sound with Alaska Native men and women 
(223). The treatment includes combination NRT, and we are evalu-
ating the nicotine metabolism ratio in predicting treatment outcome. 
To promote cessation in groups particularly vulnerable to tobacco 
use, emerging research has supported the value of targeted commu-
nication (185) and regulatory policies such as reducing nicotine 
levels in cigarettes (224), discussed next.
Regulation of cigarette addictiveness: Very low nicotine 
content cigarettes
In 1994, Benowitz and Henningfield proposed the idea of federal 
regulation of the nicotine content of cigarettes to reduce levels over 
time, resulting in lower intake of nicotine and a lower level of nico-
tine dependence (225). When nicotine levels get very low, cigarettes 
would be much less addictive. Now, 25 years later, the concept of 
regulating combustible tobacco to very low levels of nicotine con-
tent is being seriously considered.
Very low nicotine content cigarettes (VLNCs) are engineered to 
have reduced yields of nicotine in the tobacco contained in the 
cigarette rod. These cigarettes deliver much lower levels of nicotine 
than earlier cigarettes that were marketed as “light” or “ultralight” 
but which in practice allowed smokers to obtain levels of nicotine 
similar to regular “full-flavor” cigarettes through compensation 
behaviors, such as blocking ventilation holes or inhaling more deeply 
(225). Reducing the nicotine content of cigarettes to approximately 
0.5 mg per cigarette is believed to render cigarettes minimally 
addictive and lead to lower levels of consumption, making it easier 
for smokers to quit (225). Randomized trials examining the effects 
of VLNCs have shown reductions in smoking and dependence and 
increases in quit attempts for VLNCs in comparison with standard 
nicotine cigarettes. A 6-week trial found decreases in nicotine expo-
sure and dependence on nicotine for VLNCs, decreases in craving 
during abstinence from smoking, and decreases in the number of 
cigarettes smoked without significantly increasing levels of expired 
carbon monoxide or total puff volume, which suggests minimal 
compensation behavior (226). In a randomized, parallel-arm, semi- 
blinded study of adult cigarette smokers, participants receiving 
0.05 mg/g cigarettes showed greater relief of withdrawal from 
usual-brand cigarettes than the nicotine lozenge, significantly 
higher abstinence at the 6-week follow-up than the 0.3 mg/g 
cigarette, and a similar rate of cessation as the nicotine lozenge 
(227). At 12-month follow-up, however, findings were not sus-
tained (228).
In clinical trials, VLNCs generally have lower acceptability than 
commercially available cigarettes, and these trials have encountered 
problems with nonadherence (with upward of 70% of participants 
substituting traditional cigarette brands for VLNCs) and study 
dropout rates of 25 to 45% (229, 230). Combining VLNCs with 
nicotine patches may aid with the transition to VLNCs and increase 
compliance, but doing so was not found to improve long-term quit 
rates. If the nicotine content in all cigarettes was reduced to make 
them less addictive, either through federal regulation or by the 
tobacco industry’s own initiative, then problems with adherence 
and attrition could be less of an issue and long-term cessation rates 
could be higher.
A series of laboratory and experimental studies have tested 
VLNCs with smokers, with mental illness (depression and schizo-
phrenia) and substance use (opioid use) disorders finding VLNCs 
less satisfying than usual brand cigarettes and leading to reduced 
smoking while decreasing craving, withdrawal, and depressive symp-
toms and without leading to compensatory smoking (224). In one 
study that found negative cognitive performance associated with 
VLNCs, use of the nicotine patch reversed the decrements (231). 
The findings support FDA-mandated reduction in the nicotine 
content of cigarettes to a minimally addictive level to reduce ciga-
rette use among smokers with mental illness.
The Family Smoking Prevention and Tobacco Control Act bars 
the FDA from completely removing nicotine from cigarettes. The 
FDA, however, is allowed to reduce the amount of nicotine in ciga-
rettes to very low levels. In July 2017, the FDA indicated that it 
would issue an Advance Notice of Proposed Rulemaking to seek 
input on the potential public health benefits and any possible adverse 
effects from lowering the nicotine content of cigarettes (232). The 
process of review continues. The WHO emphasizes that a nicotine 
reduction strategy ought to cover all combustible tobacco products, 
not just cigarettes; include provision of tobacco cessation treat-
ment; and consider toxicant exposures from switching to noncom-
bustible forms of tobacco to sustain nicotine intake and for what 
duration (233).
The future of e-cigarettes and public health impact
The overall impact of e-cigarettes on public health remains a ques-
tion of debate. While e-cigarettes may have adverse effects on respi-
ratory health and possibly other diseases, the harm is generally 
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accepted to be much less than that of cigarette smoking (24). 
Thus, if smokers were to switch completely to e-cigarettes, then 
smoking-related disease is predicted to decrease substantially. 
Population-based models of the impact of e-cigarette use predict 
an overall health benefit, because many smokers will quit, while 
those who continue vaping or take up e-cigarettes anew experi-
ence much less harm (234). On the other hand, many parents, 
pediatricians, public health officials, and others are extremely con-
cerned about youth uptake of e-cigarettes and are encouraging local 
communities to ban e-cigarette sales. E-cigarette use in youth shows 
exposure to toxins with concern about the long-term health ef-
fects from sustained use (235). The overall benefit versus risk for 
a community is likely to depend on the prevalence of cigarette 
smoking in the community. Where smoking prevalence is high, 
the potential benefits of e-cigarettes in reducing smoking are high. 
Where smoking prevalence is low, the benefit is low and the poten-
tial risk of e-cigarettes to youth becomes the major community 
concern.
Another consideration regarding e-cigarettes is a role that it 
may play in a broader public health regulatory intervention. 
Reducing the nicotine content of combustible tobacco would make 
the products less satisfying to smokers. The availability of less 
harmful noncombusted sources of nicotine, such as e-cigarettes, 
could help a smoker transfer their nicotine addiction from com-
bustibles to e-cigarettes. Presumably, many, if not most, people 
would stop smoking, and the result would be prevention of most 
tobacco-related disease. In time, a former smoker who switched 
to e-cigarettes could quit nicotine use or remain a long-term 
e-cigarette user but with much less harm than from smoking 
cigarettes.
In closing, with the evolving nicotine product market, critically 
important is the need for evidence to inform innovations in tobacco 
control policies and tobacco treatment approaches (behavioral, 
pharmacologic, and technology based), with consideration of the 
risks and benefits for all populations affected.
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